

Siegfried Kasper

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1570572/siegfried-kasper-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

848

papers

28,262

citations

84

h-index

126

g-index

1,004

ext. papers

32,928

ext. citations

4.2

avg. IF

7.1

L-index

#	Paper	IF	Citations
848	Intravenous Esketamine Leads to an Increase in Impulsive and Suicidal Behavior in a Patient with Recurrent Major Depression and Borderline Personality Disorder.. <i>World Journal of Biological Psychiatry</i> , 2022 , 1-9	3.8	0
847	The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries.. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022 , 1	5.1	2
846	Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study.. <i>European Neuropsychopharmacology</i> , 2022 , 56, 100-111	1.2	2
845	Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study. <i>Journal of Affective Disorders</i> , 2022 , 296, 485-492	6.6	
844	Dear Doctor Letters regarding citalopram and escitalopram: guidelines vs real-world data.. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022 , 1	5.1	1
843	Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytochemicals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce.. <i>World Journal of Biological Psychiatry</i> , 2022 , 1-32	3.8	5
842	Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited.. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022 , 1	5.1	1
841	Initiating Antidepressant Medication: What is the Most Important Factor?. <i>Advances in Therapy</i> , 2022 , 1	4.1	
840	Sick leave duration as a potential marker of functionality and disease severity in depression.. <i>International Journal of Psychiatry in Clinical Practice</i> , 2022 , 1-11	2.4	1
839	Is treatment-resistant depression really resistant?. <i>European Neuropsychopharmacology</i> , 2022 , 58, 44-46	1.2	1
838	BDNF gene polymorphisms predicting treatment response to CBT-based rehabilitation of depression: to be submitted to: <i>European Neuropsychopharmacology</i> .. <i>European Neuropsychopharmacology</i> , 2022 , 58, 103-108	1.2	0
837	Cariprazine for treating psychosis: an updated meta-analysis.. <i>International Journal of Psychiatry in Clinical Practice</i> , 2022 , 1-3	2.4	
836	A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?. <i>World Journal of Biological Psychiatry</i> , 2021 , 22, 483-494	3.8	11
835	Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance. <i>World Journal of Biological Psychiatry</i> , 2021 , 22, 468-482	3.8	13
834	A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. <i>European Neuropsychopharmacology</i> , 2021 , 55, 86-95	1.2	3
833	Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 114, 110480	5.5	1
832	Letter to BJPsych in response to Horowitz and Moncrieff.. <i>British Journal of Psychiatry</i> , 2021 , 219, 619-620	3.4	

831	Obituary [Prof. Dr. Hanns Hippus (1925 -2021). <i>International Journal of Neuropsychopharmacology</i> , 2021 , 24, 856-857	5.8	78
830	The Choice of either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients with Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2021 ,	5.8	1
829	The Impact of Genetic Polymorphisms on Neuroreceptor Binding: Results from PET and SPECT Neuroreceptor Imaging Studies 2021 , 153-190		
828	Urological adverse drug reactions of psychotropic medication in psychiatric inpatients - A drug surveillance report from German-speaking countries. <i>Journal of Psychiatric Research</i> , 2021 , 144, 412-420 ^{5.2}		0
827	Neuroimaging in Seasons and Winter Depression 2021 , 245-259		
826	The Influence of Acute SSRI Administration on White Matter Microstructure in Patients Suffering From Major Depressive Disorder and Healthy Controls. <i>International Journal of Neuropsychopharmacology</i> , 2021 , 24, 542-550	5.8	5
825	Translating the immediate effects of S-Ketamine using hippocampal subfield analysis in healthy subjects-results of a randomized controlled trial. <i>Translational Psychiatry</i> , 2021 , 11, 200	8.6	4
824	The Role of Relationship Status in Major Depressive Disorder - Results of the European Group for the Study of Resistant Depression. <i>Journal of Affective Disorders</i> , 2021 , 286, 149-157	6.6	3
823	Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. <i>American Journal of Psychiatry</i> , 2021 , 178, 383-399	11.9	67
822	Reliability of task-specific neuronal activation assessed with functional PET, ASL and BOLD imaging. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021 , 41, 2986-2999	7.3	1
821	Sex-related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression. <i>Depression and Anxiety</i> , 2021 , 38, 896-906	8.4	5
820	How to prevent and manage hyperammonemic encephalopathies in valproate therapy. <i>Journal of Affective Disorders Reports</i> , 2021 , 5, 100186	1.4	1
819	Modeling psychological function in patients with schizophrenia with the PANSS: an international multi-center study. <i>CNS Spectrums</i> , 2021 , 26, 290-298	1.8	4
818	Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 104, 110050	5.5	6
817	Silexan does not affect driving performance after single and multiple dose applications: Results from a double-blind, placebo and reference-controlled study in healthy volunteers. <i>Journal of Psychiatric Research</i> , 2021 , 136, 543-551	5.2	2
816	Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression. <i>Journal of Affective Disorders</i> , 2021 , 279, 722-729	6.6	2
815	Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 108, 110170	5.5	9
814	Reconceptualising treatment-resistant depression as difficult-to-treat depression. <i>Lancet Psychiatry</i> , 2021 , 8, 14-15	23.3	7

813	No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial. <i>International Journal of Neuropsychopharmacology</i> , 2021 , 24, 171-180	5.8	3
812	Combining machine learning algorithms for prediction of antidepressant treatment response. <i>Acta Psychiatrica Scandinavica</i> , 2021 , 143, 36-49	6.5	9
811	Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II). <i>International Journal of Neuropsychopharmacology</i> , 2021 , 24, 22-31	5.8	113
810	Association of norepinephrine transporter methylation with in vivo NET expression and hyperactivity-impulsivity symptoms in ADHD measured with PET. <i>Molecular Psychiatry</i> , 2021 , 26, 1009-1018	15.1	11
809	Disrupted relationship between blood glucose and brain dopamine D2/3 receptor binding in patients with first-episode schizophrenia. <i>NeuroImage: Clinical</i> , 2021 , 32, 102813	5.3	0
808	Plant-based Medicines (Phytoceuticals) in the Treatment of Psychiatric Disorders: A Meta-review of Meta-analyses of Randomized Controlled Trials: Les médicaments à base de plantes (phytoceutiques) dans le traitement des troubles psychiatriques: une méta-revue des méta-analyses de essais cliniques randomisés contrôlés. <i>Journal of Clinical Psychopharmacology</i> , 2021 , 41, 819-819	4.8	3
807	Therapeutic effects of Silexan on somatic symptoms and physical health in patients with anxiety disorders: A meta-analysis. <i>Brain and Behavior</i> , 2021 , 11, e01997	3.4	5
806	Case Report: Bupropion Reduces the [1]FP-CIT Binding to Striatal Dopamine Transporter. <i>Frontiers in Psychiatry</i> , 2021 , 12, 631357	5	1
805	Subsyndromal generalised anxiety disorder: operationalisation and epidemiology - a systematic literature survey. <i>International Journal of Psychiatry in Clinical Practice</i> , 2021 , 1-10	2.4	1
804	Meta-analysis of brain structural changes after electroconvulsive therapy in depression. <i>Brain Stimulation</i> , 2021 , 14, 927-937	5.1	5
803	Melancholic features in major depression - a European multicenter study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 110, 110285	5.5	3
802	Gender, age at onset, and duration of being ill as predictors for the long-term course and outcome of schizophrenia: an international multicenter study. <i>CNS Spectrums</i> , 2021 , 1-8	1.8	1
801	Monoamino Oxidase A Gene Single-Nucleotide Polymorphisms and Methylation Status and the Risk of Violent Suicide Attempts in Affective Disorder Patients. <i>Frontiers in Psychiatry</i> , 2021 , 12, 667191	5	
800	Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression. <i>Current Medicinal Chemistry</i> , 2021 , 28, 4296-4320	4.3	1
799	Identifying the Common Genetic Basis of Antidepressant Response. <i>Biological Psychiatry Global Open Science</i> , 2021 ,		4
798	Predictors of sick leave days in patients affected by major depressive disorder receiving antidepressant treatment in general practice setting in Germany. <i>International Journal of Psychiatry in Clinical Practice</i> , 2021 , 25, 393-402	2.4	1
797	Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression. <i>Journal of Psychiatric Research</i> , 2021 , 141, 167-175	5.2	3
796	Association of dopamine D receptor binding potential measured using PET and [C]-(+)-PHNO with post-mortem DRD gene expression in the human brain. <i>NeuroImage</i> , 2020 , 223, 117270	7.9	5

795	The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia. <i>CNS Spectrums</i> , 2020 , 1-25	1.8	6
794	Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment. <i>International Journal of Neuropsychopharmacology</i> , 2020 , 23, 440-445	5.8	11
793	Topologically Guided Prioritization of Candidate Gene Transcripts Coexpressed with the 5-HT1A Receptor by Combining In Vivo PET and Allen Human Brain Atlas Data. <i>Cerebral Cortex</i> , 2020 , 30, 3771-3780	5.1	6
792	A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping. <i>Translational Psychiatry</i> , 2020 , 10, 50	8.6	16
791	The identification, assessment and management of difficult-to-treat depression: An international consensus statement. <i>Journal of Affective Disorders</i> , 2020 , 267, 264-282	6.6	64
790	On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D receptor agonist radioligand study. <i>Translational Psychiatry</i> , 2020 , 10, 2	8.6	17
789	Molecular neuroimaging of the serotonergic system with Positron Emission Tomography. <i>Handbook of Behavioral Neuroscience</i> , 2020 , 31, 175-194	0.7	1
788	Genetic variants associated with psychotic symptoms across psychiatric disorders. <i>Neuroscience Letters</i> , 2020 , 720, 134754	3.3	4
787	Management of mild cognitive impairment (MCI): The need for national and international guidelines. <i>World Journal of Biological Psychiatry</i> , 2020 , 21, 579-594	3.8	33
786	Machine learning classification of ADHD and HC by multimodal serotonergic data. <i>Translational Psychiatry</i> , 2020 , 10, 104	8.6	17
785	A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2020 , 35, 137-146	2.2	12
784	Adverse effects of Δ^9 -tetrahydrocannabinol on neuronal bioenergetics during postnatal development. <i>JCI Insight</i> , 2020 , 5,	9.9	9
783	Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). <i>Journal of Clinical Psychiatry</i> , 2020 , 81,	4.6	59
782	Reconfiguration of functional brain networks and metabolic cost converge during task performance. <i>ELife</i> , 2020 , 9,	8.9	15
781	Life-long epigenetic programming of cortical architecture by maternal Western diet during pregnancy. <i>Molecular Psychiatry</i> , 2020 , 25, 22-36	15.1	14
780	Changes in White Matter Microstructure After Electroconvulsive Therapy for Treatment-Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , 2020 , 23, 20-25	5.8	6
779	Social dysfunction in mood disorders and schizophrenia: Clinical modulators in four independent samples. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020 , 99, 109835	5.5	7
778	The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2020 , 23, 230-256	5.8	11

777	Add-on benzodiazepine treatment in patients with major depressive disorder - results from a European cross-sectional multicenter study. <i>European Neuropsychopharmacology</i> , 2020 , 41, 70-80	1.2	9
776	Torgny Svensson, a superb mind and an inspiring colleague. <i>International Journal of Neuropsychopharmacology</i> , 2020 , 23, 543-544	5.8	78
775	Oral Ketamine as a Treatment Option in Patients With Treatment Resistant Depression and Comorbid Arterial Hypertension. <i>Journal of Clinical Psychopharmacology</i> , 2020 , 40, 418-420	1.7	0
774	Predicting Antidepressant Citalopram Treatment Response via Changes in Brain Functional Connectivity After Acute Intravenous Challenge. <i>Frontiers in Computational Neuroscience</i> , 2020 , 14, 5541-5551	3.5	5
773	Prognosis and Improved Outcomes in Major Depression: A Review. <i>Focus (American Psychiatric Publishing)</i> , 2020 , 18, 220-235	1.1	7
772	Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , 2020 , 23, 571-577	5.8	2
771	Cardiovascular Adverse Reactions During Antipsychotic Treatment: Results of AMSP, A Drug Surveillance Program Between 1993 and 2013. <i>International Journal of Neuropsychopharmacology</i> , 2020 , 23, 67-75	5.8	9
770	The Efficacy of Light Therapy in the Treatment of Seasonal Affective Disorder: A Meta-Analysis of Randomized Controlled Trials. <i>Psychotherapy and Psychosomatics</i> , 2020 , 89, 17-24	9.4	32
769	Hippocampal GABA levels correlate with retrieval performance in an associative learning paradigm. <i>NeuroImage</i> , 2020 , 204, 116244	7.9	16
768	Brain glucose uptake during transcranial direct current stimulation measured with functional [F]FDG-PET. <i>Brain Imaging and Behavior</i> , 2020 , 14, 477-484	4.1	3
767	Sex Matters: A Multivariate Pattern Analysis of Sex- and Gender-Related Neuroanatomical Differences in Cis- and Transgender Individuals Using Structural Magnetic Resonance Imaging. <i>Cerebral Cortex</i> , 2020 , 30, 1345-1356	5.1	12
766	Extrapyramidal reactions following treatment with antidepressants: Results of the AMSP multinational drug surveillance programme. <i>World Journal of Biological Psychiatry</i> , 2020 , 21, 308-316	3.8	7
765	Manifesto for an international digital mental health network 2019 , 2, 14-24		11
764	Predicting Ventral Striatal Activation During Reward Anticipation From Functional Connectivity at Rest. <i>Frontiers in Human Neuroscience</i> , 2019 , 13, 289	3.3	1
763	Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study. <i>International Journal of Neuropsychopharmacology</i> , 2019 , 22, 681-697	5.8	18
762	High occupational level is associated with poor response to the treatment of depression: A replication study. <i>European Neuropsychopharmacology</i> , 2019 , 29, 349-355	1.2	2
761	Seasonality of antidepressant prescriptions and sick leaves. <i>Journal of Psychiatric Research</i> , 2019 , 111, 128-133	5.2	3
760	Epistasis of HTR1A and BDNF risk genes alters cortical 5-HT1A receptor binding: PET results link genotype to molecular phenotype in depression. <i>Translational Psychiatry</i> , 2019 , 9, 5	8.6	5

759	Choosing among second-generation antidepressant treatments for depressed patients with cardiac diseases. <i>International Journal of Psychiatry in Clinical Practice</i> , 2019 , 23, 134-148	2.4	2
758	Hippocampal Subfields in Acute and Remitted Depression-an Ultra-High Field Magnetic Resonance Imaging Study. <i>International Journal of Neuropsychopharmacology</i> , 2019 , 22, 513-522	5.8	11
757	Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging. <i>European Neuropsychopharmacology</i> , 2019 , 29, 711-719	1.2	8
756	Characterization of pharmacological response to selective serotonin reuptake inhibitors using clustering of resting-state hybrid PET/MR data. <i>European Neuropsychopharmacology</i> , 2019 , 29, S603-S604 ^{1,2}		
755	Major Depression and Comorbid Diabetes - Findings from the European Group for the Study of Resistant Depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019 , 94, 109638 ^{5,5}	5.5	11
754	Comorbid hypertension in patients with major depressive disorder - Results from a European multicenter study. <i>European Neuropsychopharmacology</i> , 2019 , 29, 777-785	1.2	12
753	A case-control study of paternal and maternal age as risk factors in mood disorders. <i>International Journal of Psychiatry in Clinical Practice</i> , 2019 , 23, 90-98	2.4	8
752	Acute and subsequent continuation electroconvulsive therapy elevates serum BDNF levels in patients with major depression. <i>Brain Stimulation</i> , 2019 , 12, 1041-1050	5.1	18
751	Temperament and character influence on depression treatment outcome. <i>Journal of Affective Disorders</i> , 2019 , 252, 464-474	6.6	14
750	On the suitability of medical analogies, from hypertension to broken leg. <i>World Journal of Biological Psychiatry</i> , 2019 , 20, 171-172	3.8	3
749	Prognosis and improved outcomes in major depression: a review. <i>Translational Psychiatry</i> , 2019 , 9, 127	8.6	127
748	Prefrontal networks dynamically related to recovery from major depressive disorder: a longitudinal pharmacological fMRI study. <i>Translational Psychiatry</i> , 2019 , 9, 64	8.6	20
747	Personalised and precision psychiatry: what do the CINP bipolar guidelines suggest?. <i>International Journal of Psychiatry in Clinical Practice</i> , 2019 , 23, 80-81	2.4	1
746	Usage of Therapeutic Sleep Deprivation: A Survey in Psychiatric Hospitals in Austria, Germany, and Switzerland. <i>Behavioral Sleep Medicine</i> , 2019 , 17, 713-720	4.2	6
745	Results of the European Group for the Study of Resistant Depression (GSRD) - basis for further research and clinical practice. <i>World Journal of Biological Psychiatry</i> , 2019 , 20, 427-448	3.8	51
744	Association between dynamic resting-state functional connectivity and ketamine plasma levels in visual processing networks. <i>Scientific Reports</i> , 2019 , 9, 11484	4.9	7
743	Repetitive enhancement of serum BDNF subsequent to continuation ECT. <i>Acta Psychiatrica Scandinavica</i> , 2019 , 140, 426-434	6.5	11
742	Changes over time of the diagnostic and therapeutic characteristics of patients of a psychiatric intensive care unit in Austria. <i>Comprehensive Psychiatry</i> , 2019 , 93, 20-26	7.3	3

741	Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR. <i>Frontiers in Molecular Neuroscience</i> , 2019 , 12, 172	6.1	3
740	Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. <i>European Neuropsychopharmacology</i> , 2019 , 29, 971-985	1.2	44
739	Psychopharmacological Treatment of Schizophrenia Over Time in 30 908 Inpatients: Data From the AMSP Study. <i>International Journal of Neuropsychopharmacology</i> , 2019 , 22, 560-573	5.8	17
738	Alcohol consumption in Austrian physicians. <i>Annals of General Psychiatry</i> , 2019 , 18, 22	3.4	6
737	Psychotic Features in Patients With Major Depressive Disorder: A Report From the European Group for the Study of Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2019 , 80,	4.6	18
736	Big Data Guided Interventions: Predicting Treatment Response 2019 , 53-76		3
735	Attenuation Correction Approaches for Serotonin Transporter Quantification With PET/MRI. <i>Frontiers in Physiology</i> , 2019 , 10, 1422	4.6	5
734	Attrition in treatment-resistant depression: predictors and clinical impact. <i>International Clinical Psychopharmacology</i> , 2019 , 34, 161-169	2.2	
733	Efficacy of Add-on Pregabalin in the Treatment of Patients with Generalized Anxiety Disorder and Unipolar Major Depression With an Early Nonresponse to Escitalopram: A Double-Blind Placebo-Controlled Study. <i>Pharmacopsychiatry</i> , 2019 , 52, 193-202	2	5
732	Circuit Mechanisms of Reward, Anhedonia, and Depression. <i>International Journal of Neuropsychopharmacology</i> , 2019 , 22, 105-118	5.8	60
731	Making Sense of Connectivity. <i>International Journal of Neuropsychopharmacology</i> , 2019 , 22, 194-207	5.8	12
730	WFSBP guidelines on how to grade treatment evidence for clinical guideline development. <i>World Journal of Biological Psychiatry</i> , 2019 , 20, 2-16	3.8	15
729	Updated European Consensus Statement on diagnosis and treatment of adult ADHD. <i>European Psychiatry</i> , 2019 , 56, 14-34	6	170
728	Definition of treatment-resistant depression - Asia Pacific perspectives. <i>Journal of Affective Disorders</i> , 2019 , 245, 626-636	6.6	23
727	Structural changes in amygdala nuclei, hippocampal subfields and cortical thickness following electroconvulsive therapy in treatment-resistant depression: longitudinal analysis. <i>British Journal of Psychiatry</i> , 2019 , 214, 159-167	5.4	48
726	Cutaneous adverse drug reactions to psychotropic drugs and their risk factors - a case-control study. <i>European Neuropsychopharmacology</i> , 2019 , 29, 111-121	1.2	5
725	Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. <i>British Journal of Psychiatry</i> , 2019 , 214, 36-41	5.4	24
724	The effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography. <i>Brain Stimulation</i> , 2019 , 12, 714-723	5.1	13

7 ²³	Parcellation of the Human Cerebral Cortex Based on Molecular Targets in the Serotonin System Quantified by Positron Emission Tomography In vivo. <i>Cerebral Cortex</i> , 2019 , 29, 372-382	5.1	7
7 ²²	Opinion paper: poor response to treatment of depression in people in high occupational levels. <i>Psychological Medicine</i> , 2019 , 49, 49-54	6.9	6
7 ²¹	Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition. <i>British Journal of Psychiatry</i> , 2019 , 214, 27-35	5.4	33
7 ²⁰	Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. <i>Acta Psychiatrica Scandinavica</i> , 2019 , 139, 78-88	6.5	52
7 ¹⁹	Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019 , 269, 183-193	5.1	27
7 ¹⁸	The pulvinar nucleus and antidepressant treatment: dynamic modeling of antidepressant response and remission with ultra-high field functional MRI. <i>Molecular Psychiatry</i> , 2019 , 24, 746-756	15.1	14
7 ¹⁷	The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives. <i>International Journal of Neuropsychopharmacology</i> , 2019 , 22, 93-104	5.8	14
7 ¹⁶	Therapeutic efficacy of the Ginkgo special extract EGb761 within the framework of the mitochondrial cascade hypothesis of Alzheimer® disease. <i>World Journal of Biological Psychiatry</i> , 2019 , 20, 173-189	3.8	33
7 ¹⁵	Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD). <i>International Journal of Neuropsychopharmacology</i> , 2018 , 21, 539-549	5.8	32
7 ¹⁴	Clinical correlates of augmentation/combination treatment strategies in major depressive disorder. <i>Acta Psychiatrica Scandinavica</i> , 2018 , 137, 401-412	6.5	25
7 ¹³	Anti-Oxidative Effects of Melatonin Receptor Agonist and Omega-3 Polyunsaturated Fatty Acids in Neuronal SH-SY5Y Cells: Deciphering Synergic Effects on Anti-Depressant Mechanisms. <i>Molecular Neurobiology</i> , 2018 , 55, 7271-7284	6.2	17
7 ¹²	Stress management and the role of : a review. <i>International Journal of Psychiatry in Clinical Practice</i> , 2018 , 22, 242-252	2.4	21
7 ¹¹	Assessment of Ketamine Binding of the Serotonin Transporter in Humans with Positron Emission Tomography. <i>International Journal of Neuropsychopharmacology</i> , 2018 , 21, 145-153	5.8	12
7 ¹⁰	The Impact of COMT and Childhood Maltreatment on Suicidal Behaviour in Affective Disorders. <i>Scientific Reports</i> , 2018 , 8, 692	4.9	9
7 ⁰⁹	Probing the association between serotonin-1A autoreceptor binding and amygdala reactivity in healthy volunteers. <i>NeuroImage</i> , 2018 , 171, 1-5	7.9	6
7 ⁰⁸	Comorbid thyroid disease in patients with major depressive disorder - results from the European Group for the Study of Resistant Depression (GSRD). <i>European Neuropsychopharmacology</i> , 2018 , 28, 752-760	1.2	25
7 ⁰⁷	DiGeorge syndrome : Relevance of psychiatric symptoms in undiagnosed adult patients. <i>Wiener Klinische Wochenschrift</i> , 2018 , 130, 283-287	2.3	8
7 ⁰⁶	Spatial analysis and high resolution mapping of the human whole-brain transcriptome for integrative analysis in neuroimaging. <i>NeuroImage</i> , 2018 , 176, 259-267	7.9	45

705	Venous thromboembolism during treatment with antipsychotics: Results of a drug surveillance programme. <i>World Journal of Biological Psychiatry</i> , 2018 , 19, 175-186	3.8	11
704	Silexan in anxiety disorders: Clinical data and pharmacological background. <i>World Journal of Biological Psychiatry</i> , 2018 , 19, 412-420	3.8	76
703	Paternal and maternal age as risk factors for schizophrenia: a case-control study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2018 , 22, 170-176	2.4	15
702	Low comorbid obsessive-compulsive disorder in patients with major depressive disorder - Findings from a European multicenter study. <i>Journal of Affective Disorders</i> , 2018 , 227, 254-259	6.6	5
701	Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018 , 81, 203-210	5.5	20
700	Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. <i>World Journal of Biological Psychiatry</i> , 2018 , 19, 330-348	3.8	20
699	Effects of testosterone treatment on hypothalamic neuroplasticity in female-to-male transgender individuals. <i>Brain Structure and Function</i> , 2018 , 223, 321-328	4	13
698	Influence of CRHR1 Polymorphisms and Childhood Abuse on Suicide Attempts in Affective Disorders: A GxE Approach. <i>Frontiers in Psychiatry</i> , 2018 , 9, 165	5	6
697	Striatal dopaminergic alterations in Tourette syndrome: a meta-analysis based on 16 PET and SPECT neuroimaging studies. <i>Translational Psychiatry</i> , 2018 , 8, 143	8.6	20
696	Diversity matters: combinatorial information coding by GABA receptor subunits during spatial learning and its allosteric modulation. <i>Cellular Signalling</i> , 2018 , 50, 142-159	4.9	4
695	Rapid antidepressant effect of S-ketamine in schizophrenia. <i>European Neuropsychopharmacology</i> , 2018 , 28, 980-982	1.2	6
694	International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets. <i>Pharmacological Reviews</i> , 2018 , 70, 475-504	22.5	31
693	Task-relevant brain networks identified with simultaneous PET/MR imaging of metabolism and connectivity. <i>Brain Structure and Function</i> , 2018 , 223, 1369-1378	4	27
692	Refining Prediction in Treatment-Resistant Depression: Results of Machine Learning Analyses in the TRD III Sample. <i>Journal of Clinical Psychiatry</i> , 2018 , 79,	4.6	58
691	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2018 , 19, 2-58	3.8	89
690	Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2018 , 227, 777-786	6.6	20
689	Implementing prevention of seasonal affective disorder from patients and physicians perspectives - a qualitative study. <i>BMC Psychiatry</i> , 2018 , 18, 372	4.2	7
688	The serotonin transporter and the activity regulated cytoskeleton-associated protein genes in antidepressant response and resistance: 5-HTTLPR and other variants. <i>Human Psychopharmacology</i> , 2018 , 33, e2682	2.3	6

687	Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression - Results from a European multicenter study. <i>European Neuropsychopharmacology</i> , 2018 , 28, 1305-1313	1.2	13
686	Prediction of Autopsy Verified Neuropathological Change of Alzheimer® Disease Using Machine Learning and MRI. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 406	5.3	10
685	Brain monoamine oxidase A in seasonal affective disorder and treatment with bright light therapy. <i>Translational Psychiatry</i> , 2018 , 8, 198	8.6	14
684	Evidence for the Efficacy of Bright Light Therapy for Bipolar Depression. <i>American Journal of Psychiatry</i> , 2018 , 175, 905-906	11.9	9
683	Suicidal Ideation and Suicidal Behavior as Rare Adverse Events of Antidepressant Medication: Current Report from the AMSP Multicenter Drug Safety Surveillance Project. <i>International Journal of Neuropsychopharmacology</i> , 2018 , 21, 814-821	5.8	17
682	Reduced task durations in functional PET imaging with [F]FDG approaching that of functional MRI. <i>NeuroImage</i> , 2018 , 181, 323-330	7.9	30
681	A proposal for a psychopharmacology-pharmacotherapy catalogue of learning objectives and a curriculum in Europe. <i>World Journal of Biological Psychiatry</i> , 2017 , 18, 29-38	3.8	11
680	Administration of ketamine for unipolar and bipolar depression. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017 , 21, 2-12	2.4	62
679	Higher than recommended dosages of antipsychotics in male patients with schizophrenia are associated with increased depression but no major neurocognitive side effects: Results of a cross-sectional pilot naturalistic study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017 , 75, 113-119	5.5	2
678	Default mode network deactivation during emotion processing predicts early antidepressant response. <i>Translational Psychiatry</i> , 2017 , 7, e1008	8.6	40
677	Simple and rapid quantification of serotonin transporter binding using [C]DASB bolus plus constant infusion. <i>NeuroImage</i> , 2017 , 149, 23-32	7.9	16
676	Electroconvulsive therapy with S-ketamine anesthesia for catatonia in coexisting depression and dementia. <i>International Psychogeriatrics</i> , 2017 , 29, 1223-1225	3.4	2
675	Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study. <i>Journal of Psychiatric Research</i> , 2017 , 91, 1-13	5.2	46
674	Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017 , 267, 723-735	5.1	14
673	Effects of sex hormone treatment on white matter microstructure in individuals with gender dysphoria. <i>NeuroImage</i> , 2017 , 150, 60-67	7.9	18
672	A new nomenclature for classifying psychotropic drugs. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1614-1616	3.8	15
671	Silexan does not cause withdrawal symptoms even when abruptly discontinued. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017 , 21, 177-180	2.4	7
670	Association of Protein Distribution and Gene Expression Revealed by PET and Post-Mortem Quantification in the Serotonergic System of the Human Brain. <i>Cerebral Cortex</i> , 2017 , 27, 117-130	5.1	20

669	Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis. <i>International Clinical Psychopharmacology</i> , 2017 , 32, 49-55	2.2	37
668	The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes - Results from a cross-sectional European multicenter study. <i>European Neuropsychopharmacology</i> , 2017 , 27, 625-632	1.2	14
667	The influence of the rs6295 gene polymorphism on serotonin-1A receptor distribution investigated with PET in patients with major depression applying machine learning. <i>Translational Psychiatry</i> , 2017 , 7, e1150	8.6	16
666	Norepinephrine transporter gene and protein expression of the human brain investigated with postmortem data and PET. <i>European Neuropsychopharmacology</i> , 2017 , 27, S73-S74	1.2	
665	Serotonin and neuroplasticity - Links between molecular, functional and structural pathophysiology in depression. <i>Neuroscience and Biobehavioral Reviews</i> , 2017 , 77, 317-326	9	181
664	Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision. <i>World Journal of Biological Psychiatry</i> , 2017 , 18, 86-119	3.8	38
663	Imaging the neuroplastic effects of ketamine with VBM and the necessity of placebo control. <i>NeuroImage</i> , 2017 , 147, 198-203	7.9	16
662	Dose Escalation of Antidepressants in Unipolar Depression: A Meta-Analysis of Double-Blind, Randomized Controlled Trials. <i>Psychotherapy and Psychosomatics</i> , 2017 , 86, 283-291	9.4	25
661	The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study. <i>International Journal of Neuropsychopharmacology</i> , 2017 , 20, 782-787	5.8	8
660	Multicenter, open-label, exploratory clinical trial with extract in patients suffering from burnout symptoms. <i>Neuropsychiatric Disease and Treatment</i> , 2017 , 13, 889-898	3.1	12
659	Prevention of seasonal affective disorder in daily clinical practice: results of a survey in German-speaking countries. <i>BMC Psychiatry</i> , 2017 , 17, 247	4.2	9
658	The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm. <i>International Journal of Neuropsychopharmacology</i> , 2017 , 20, 121-179	5.8	61
657	The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 1: Background and Methods of the Development of Guidelines. <i>International Journal of Neuropsychopharmacology</i> , 2017 , 20, 98-120	5.8	19
656	The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 4: Unmet Needs in the Treatment of Bipolar Disorder and Recommendations for Future Research. <i>International Journal of Neuropsychopharmacology</i> , 2017 , 20, 196-205	5.8	36
655	Systematic evaluation of dose-escalation strategies after initial non-response to standard-dose pharmacotherapy in schizophrenia. <i>European Psychiatry</i> , 2017 , 41, S193-S193	6	
654	Alternating intravenous racemic ketamine and electroconvulsive therapy in treatment resistant depression: A case report. <i>European Psychiatry</i> , 2017 , 41, S522-S522	6	
653	Robust Antidepressant Effect Following Alternating Intravenous Racemic Ketamine and Electroconvulsive Therapy in Treatment-Resistant Depression: A Case Report. <i>Journal of ECT</i> , 2017 , 33, e31-e32	2	4
652	Case Report: ECT in a Patient With Primary Parkinsonian Syndrome and Schizophrenia. <i>Journal of ECT</i> , 2017 , 33, e2-e3	2	0

651	Editorial. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017 , 21, 1	2.4	2
650	Ketamine for the Treatment of Depression. <i>JAMA Psychiatry</i> , 2017 , 74, 970	14.5	6
649	Evidence-based pharmacotherapy of treatment-resistant unipolar depression. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017 , 21, 13-23	2.4	60
648	Altered interregional molecular associations of the serotonin transporter in attention deficit/hyperactivity disorder assessed with PET. <i>Human Brain Mapping</i> , 2017 , 38, 792-802	5.9	13
647	Ketamine-dependent neuronal activation in healthy volunteers. <i>Brain Structure and Function</i> , 2017 , 222, 1533-1542	4	27
646	Has the existence of seasonal affective disorder been disproven?. <i>Journal of Affective Disorders</i> , 2017 , 208, 54-55	6.6	11
645	Making Sense of: Sensitization in Schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2017 , 20, 1-10	5.8	21
644	Monoamine oxidase A distribution volume as a correlate for electroconvulsive therapy □ preliminary results. <i>European Neuropsychopharmacology</i> , 2017 , 27, S708-S709	1.2	1
643	Influence of serotonergic gene variants on serotonin transporter binding in ADHD. <i>European Neuropsychopharmacology</i> , 2017 , 27, S707	1.2	
642	Reduced gray matter in subcortical brain regions in MDD: preliminary results of an ultra-high field 7 Tesla MRI Study. <i>European Neuropsychopharmacology</i> , 2017 , 27, S719-S720	1.2	
641	Investigating dose dependency of ketamine binding on the serotonin transporter with positron emission tomography. <i>European Neuropsychopharmacology</i> , 2017 , 27, S779	1.2	
640	Effects of Selective Serotonin Reuptake Inhibitors on Interregional Relation of Serotonin Transporter Availability in Major Depression. <i>Frontiers in Human Neuroscience</i> , 2017 , 11, 48	3.3	41
639	A New Prediction Model for Evaluating Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, 215-222	4.6	49
638	Silexan in generalized anxiety disorder: investigation of the therapeutic dosage range in a pooled data set. <i>International Clinical Psychopharmacology</i> , 2017 , 32, 195-204	2.2	17
637	Elektrokonvulsionstherapie, Hirnstimulationsverfahren 2017 , 1-46		
636	Lichttherapie 2017 , 895-901		
635	Schlafentzugsbehandlung 2017 , 889-894		
634	Psychopharmakotherapie □klinisch-empirische Grundlagen 2017 , 795-842		

633	Elektrokonvulsionstherapie, Hirnstimulationsverfahren 2017 , 843-887		
632	The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines. <i>International Journal of Neuropsychopharmacology</i> , 2017 , 20, 180-195	5.8	102
631	Bipolar and related disorders in DSM-5 and ICD-10. <i>CNS Spectrums</i> , 2016 , 21, 318-23	1.8	14
630	Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers - A pharmacoepidemiological cross-sectional multicenter study. <i>European Neuropsychopharmacology</i> , 2016 , 26, 1960-1971	1.2	33
629	Use of Light Therapy by Office-Based Physicians. <i>Neuropsychobiology</i> , 2016 , 74, 182-187	4	5
628	Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics. <i>World Journal of Biological Psychiatry</i> , 2016 , 17, 406-28	3.8	23
627	Bipolar II disorder as a risk factor for postpartum depression. <i>Journal of Affective Disorders</i> , 2016 , 204, 54-8	6.6	22
626	Intramuscular maintenance treatment with ultra-high-dose long-acting injectable aripiprazole in an elderly patient suffering from chronic refractory schizophrenia: A case report. <i>European Psychiatry</i> , 2016 , 33, S573-S573	6	2
625	A European psychopharmacology curriculum: The young psychiatrist's point of view. <i>European Psychiatry</i> , 2016 , 33, S63-S63	6	
624	Oppositional COMT Val158Met effects on resting state functional connectivity in adolescents and adults. <i>Brain Structure and Function</i> , 2016 , 221, 103-14	4	26
623	Effects of norepinephrine transporter gene variants on NET binding in ADHD and healthy controls investigated by PET. <i>Human Brain Mapping</i> , 2016 , 37, 884-95	5.9	29
622	Epidemiology and socioeconomic impact of seasonal affective disorder in Austria. <i>European Psychiatry</i> , 2016 , 32, 28-33	6	26
621	Meta-analysis of the COMT Val158Met polymorphism in major depressive disorder: the role of gender. <i>World Journal of Biological Psychiatry</i> , 2016 , 17, 147-58	3.8	21
620	Assessment and management of agitation in psychiatry: Expert consensus. <i>World Journal of Biological Psychiatry</i> , 2016 , 17, 86-128	3.8	146
619	Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials. <i>World Journal of Biological Psychiatry</i> , 2016 , 17, 210-20	3.8	2
618	Drug-Induced Liver Injury during Antidepressant Treatment: Results of AMSP, a Drug Surveillance Program. <i>International Journal of Neuropsychopharmacology</i> , 2016 , 19,	5.8	31
617	Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study. <i>Journal of Affective Disorders</i> , 2016 , 189, 224-32	6.6	54
616	Hirnstimulationsverfahren, Elektrokonvulsionstherapie 2016 , 1-23		

615 Lichttherapie **2016**, 1-8

614 Schlafentzugsbehandlung **2016**, 1-7

613 PM478. Imaging the effects of d-amphetamine in the human brain for modelling dopaminergic alterations in schizophrenia. *International Journal of Neuropsychopharmacology*, **2016**, 19, 74-74 5.8 78

612 PS168. Hybrid PET/MR imaging of serotonin transporter occupancy and brain activation to elucidate the mechanism of action of selective serotonin reuptake inhibitors. *International Journal of Neuropsychopharmacology*, **2016**, 19, 60-61 5.8 78

611 Quantification of Task-Specific Glucose Metabolism with Constant Infusion of 18F-FDG. *Journal of Nuclear Medicine*, **2016**, 57, 1933-1940 8.9 38

610 Psychiatric patients' Perception of physical restraint. *Acta Psychiatrica Scandinavica*, **2016**, 133, 221-31 6.5 24

609 The impact of serotonin receptor 1A and 2A gene polymorphisms and interactions on suicide attempt and suicide risk in depressed patients with insufficient response to treatment--a European multicentre study. *International Clinical Psychopharmacology*, **2016**, 31, 1-7 2.2 16

608 Pregabalin in Tourette Syndrome: A Case Series. *American Journal of Psychiatry*, **2016**, 173, 1242-1243 11.9 1

607 Estradiol level changes correlate with changes in mean diffusivity and fractional anisotropy values in female-to-male transsexuals. *European Neuropsychopharmacology*, **2016**, 26, S202 1.2

606 Attenuation of habenula default mode network connectivity by selective serotonin reuptake inhibitors, a pharmacological hybrid PET/MR study. *European Neuropsychopharmacology*, **2016**, 26, S317 1.2 0

605 Efficacy of Silexan in mixed anxiety-depression--A randomized, placebo-controlled trial. *European Neuropsychopharmacology*, **2016**, 26, 331-340 1.2 40

604 Gender transition affects neural correlates of empathy: A resting state functional connectivity study with ultra high-field 7T MR imaging. *NeuroImage*, **2016**, 138, 257-265 7.9 18

603 P.1.015 Surface-based clustering of serotonergic and adrenergic receptor mRNA expression in the human cortex. *European Neuropsychopharmacology*, **2016**, 26, S15 1.2

602 The relevance of mixed anxiety and depression as a diagnostic category in clinical practice. *European Archives of Psychiatry and Clinical Neuroscience*, **2016**, 266, 725-736 5.1 50

601 Subcortical gray matter changes in transgender subjects after long-term cross-sex hormone administration. *Psychoneuroendocrinology*, **2016**, 74, 371-379 5 38

600 High occupational level is associated with poor response to treatment of depression. *European Neuropsychopharmacology*, **2016**, 26, 1320-6 1.2 7

599 Neuroscience-based Nomenclature (NbN): A call for action. *World Journal of Biological Psychiatry*, **2016**, 17, 318-20 3.8 10

598 Testosterone affects language areas of the adult human brain. *Human Brain Mapping*, **2016**, 37, 1738-48 5.9 27

597	What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram. <i>World Journal of Biological Psychiatry</i> , 2015 , 16, 472-82	3.8	14
596	Second-Generation Antipsychotic Drugs in Anorexia Nervosa: A Meta-Analysis of Randomized Controlled Trials. <i>Psychotherapy and Psychosomatics</i> , 2015 , 84, 110-116	9.4	53
595	High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People. <i>Biological Psychiatry</i> , 2015 , 78, 525-33	7.9	55
594	Pharmacotherapy of anxiety disorders in German-speaking countries: current status and changes between 1994 and 2011. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015 , 265, 199-208	5.1	3
593	The serotonin transporter in psychiatric disorders: insights from PET imaging. <i>Lancet Psychiatry</i> , 2015 , 2, 743-755	23.3	110
592	Interaction between 5-HTTLPR and 5-HT1B genotype status enhances cerebral 5-HT1A receptor binding. <i>NeuroImage</i> , 2015 , 111, 505-12	7.9	7
591	Phytopharmaceutical treatment of anxiety, depression, and dementia in the elderly: evidence from randomized, controlled clinical trials. <i>Wiener Medizinische Wochenschrift</i> , 2015 , 165, 217-28	2.9	19
590	Structural Connectivity Networks of Transgender People. <i>Cerebral Cortex</i> , 2015 , 25, 3527-34	5.1	59
589	Ketamine-Induced Modulation of the Thalamo-Cortical Network in Healthy Volunteers As a Model for Schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2015 , 18,	5.8	62
588	Neuronal cell adhesion genes and antidepressant response in three independent samples. <i>Pharmacogenomics Journal</i> , 2015 , 15, 538-48	3.5	25
587	Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: A comparison with other psychiatric disorders. <i>European Neuropsychopharmacology</i> , 2015 , 25, 763-72	1.2	46
586	Voxel-based morphometry at ultra-high fields. a comparison of 7T and 3T MRI data. <i>NeuroImage</i> , 2015 , 113, 207-16	7.9	34
585	Treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone. <i>International Clinical Psychopharmacology</i> , 2015 , 30, 14-22	2.2	6
584	Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: A report of two cases. <i>European Neuropsychopharmacology</i> , 2015 , 25, 2183-4	1.2	22
583	Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep--A randomized, placebo-controlled trial. <i>European Neuropsychopharmacology</i> , 2015 , 25, 1960-7	1.2	45
582	Comparison of continuously acquired resting state and extracted analogues from active tasks. <i>Human Brain Mapping</i> , 2015 , 36, 4053-63	5.9	19
581	Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials. <i>International Journal of Neuropsychopharmacology</i> , 2015 , 18,	5.8	66
580	P.1.i.037 Effects of norepinephrine transporter gene variants on protein binding in patients with ADHD using PET. <i>European Neuropsychopharmacology</i> , 2015 , 25, S321-S322	1.2	

579	Association study of CREB1 polymorphisms and suicidality in MDD: results from a European multicenter study on treatment resistant depression. <i>International Journal of Neuroscience</i> , 2015 , 125, 336-43	2	7
578	World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2015 , 19, 2-7	2.4	16
577	P.1.i.047 Interregional changes in serotonin transporter availability upon treatment with selective serotonin reuptake inhibitors. <i>European Neuropsychopharmacology</i> , 2015 , 25, S327-S328	1.2	
576	P.1.i.034 Gene expression and protein distribution of serotonergic key proteins in the human brain revealed by PET in vivo and postmortem quantification. <i>European Neuropsychopharmacology</i> , 2015 , 25, S319-S320	1.2	
575	Factors contributing to the increasing placebo response in antidepressant trials. <i>World Psychiatry</i> , 2015 , 14, 304-6	14.4	10
574	Influence of Sex on Suicidal Phenotypes in Affective Disorder Patients with Traumatic Childhood Experiences. <i>PLoS ONE</i> , 2015 , 10, e0137763	3.7	15
573	Dose escalation of antipsychotic drugs in schizophrenia: a meta-analysis of randomized controlled trials. <i>Schizophrenia Research</i> , 2015 , 166, 187-93	3.6	19
572	Temperament and character profiles in bipolar I, bipolar II and major depressive disorder: Impact over illness course, comorbidity pattern and psychopathological features of depression. <i>Journal of Affective Disorders</i> , 2015 , 184, 51-9	6.6	30
571	Reduced default mode network suppression during a working memory task in remitted major depression. <i>Journal of Psychiatric Research</i> , 2015 , 64, 9-18	5.2	66
570	Increasing placebo response in antipsychotic trials: a clinical perspective. <i>Evidence-Based Mental Health</i> , 2015 , 18, 77-9	11.1	8
569	Individual diversity of functional brain network economy. <i>Brain Connectivity</i> , 2015 , 5, 156-65	2.7	14
568	Report of the WPA section of pharmacopsychiatry on the relationship of antiepileptic drugs with suicidality in epilepsy. <i>International Journal of Psychiatry in Clinical Practice</i> , 2015 , 19, 158-67	2.4	17
567	The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression. <i>European Neuropsychopharmacology</i> , 2015 , 25, 441-53	1.2	58
566	(S)-citalopram influences amygdala modulation in healthy subjects: a randomized placebo-controlled double-blind fMRI study using dynamic causal modeling. <i>NeuroImage</i> , 2015 , 108, 243-50	7.8	30
565	Ähnlich stark wirksam wie synthetische Stoffe und besser verträglich?. <i>Der Neurologe Und Psychiater</i> , 2015 , 16, 39-46	0	
564	Dimensions of Delusions in Major Depression: Socio-demographic and Clinical Correlates in an Unipolar-Bipolar Sample. <i>Clinical Psychopharmacology and Neuroscience</i> , 2015 , 13, 48-52	3.4	11
563	Psychopharmakotherapie [klinisch-empirische Grundlagen 2015 , 1-48		
562	Cardiovascular adverse reactions during antidepressant treatment: a drug surveillance report of German-speaking countries between 1993 and 2010. <i>International Journal of Neuropsychopharmacology</i> , 2014 , 18,	5.8	44

561	Effects of Silexan on the serotonin-1A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging. <i>International Journal of Neuropsychopharmacology</i> , 2014 , 18,	5.8	36
560	How well do randomized controlled trial data generalize to real-world clinical practice settings? A comparison of two generalized anxiety disorder studies. <i>European Neuropsychopharmacology</i> , 2014 , 24, 125-32	1.2	6
559	Gray matter and intrinsic network changes in the posterior cingulate cortex after selective serotonin reuptake inhibitor intake. <i>NeuroImage</i> , 2014 , 84, 236-44	7.9	39
558	Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine. <i>International Journal of Neuropsychopharmacology</i> , 2014 , 17, 859-69	5.8	126
557	Compliance as a stable function in the treatment course of bipolar disorder in patients stabilized on olanzapine: results from a 24-month observational study. <i>International Journal of Bipolar Disorders</i> , 2014 , 2, 13	5.4	10
556	White matter microstructure in transsexuals and controls investigated by diffusion tensor imaging. <i>Journal of Neuroscience</i> , 2014 , 34, 15466-75	6.6	76
555	Additive gene-environment effects on hippocampal structure in healthy humans. <i>Journal of Neuroscience</i> , 2014 , 34, 9917-26	6.6	52
554	A multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinities. <i>European Neuropsychopharmacology</i> , 2014 , 24, 1463-74	1.2	13
553	Imaging brain circuits in anxiety disorders. <i>Lancet Psychiatry</i> , 2014 , 1, 251-2	23.3	3
552	Testosterone, neural circuits, and male depression. <i>Biological Psychiatry</i> , 2014 , 76, 272-3	7.9	1
551	Brain-derived neurotrophic factor (BDNF)-epigenetic regulation in unipolar and bipolar affective disorder. <i>Journal of Affective Disorders</i> , 2014 , 168, 399-406	6.6	55
550	Actigraphy in patients with treatment-resistant depression undergoing electroconvulsive therapy. <i>Journal of Psychiatric Research</i> , 2014 , 57, 96-100	5.2	14
549	PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway. <i>Pharmacogenomics Journal</i> , 2014 , 14, 463-72	3.5	31
548	Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET. <i>NeuroImage</i> , 2014 , 88, 252-62	7.9	41
547	Family history of major depression and residual symptoms in responder and non-responder depressed patients. <i>Comprehensive Psychiatry</i> , 2014 , 55, 51-5	7.3	4
546	Attenuated serotonin transporter association between dorsal raphe and ventral striatum in major depression. <i>Human Brain Mapping</i> , 2014 , 35, 3857-66	5.9	38
545	Neurotransmitters and electroconvulsive therapy. <i>Journal of ECT</i> , 2014 , 30, 116-21	2	67
544	Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder. <i>International Journal of Neuropsychopharmacology</i> , 2014 , 17, 685-95	5.8	22

543	Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in patients with schizoaffective disorder or schizophrenia: a randomized, open-label, parallel-group, flexible-dose study. <i>International Clinical Psychopharmacology</i> , 2014 , 29, 166-76	2.2	5
542	The norepinephrine transporter in attention-deficit/hyperactivity disorder investigated with positron emission tomography. <i>JAMA Psychiatry</i> , 2014 , 71, 1340-1349	14.5	35
541	Effects of hormone replacement therapy on cerebral serotonin-1A receptor binding in postmenopausal women examined with [carbonyl- ¹¹ C]WAY-100635. <i>Psychoneuroendocrinology</i> , 2014 , 45, 1-10	5	17
540	Relation of progesterone and DHEAS serum levels to 5-HT _{1A} receptor binding potential in pre- and postmenopausal women. <i>Psychoneuroendocrinology</i> , 2014 , 46, 52-63	5	16
539	Impact of COMT genotype on serotonin-1A receptor binding investigated with PET. <i>Brain Structure and Function</i> , 2014 , 219, 2017-28	4	12
538	Cerebral serotonin transporter asymmetry in females, males and male-to-female transsexuals measured by PET in vivo. <i>Brain Structure and Function</i> , 2014 , 219, 171-83	4	24
537	Platelet serotonin transporter function predicts default-mode network activity. <i>PLoS ONE</i> , 2014 , 9, e92543	4.3	16
536	Exploring the impact of BDNF Val66Met genotype on serotonin transporter and serotonin-1A receptor binding. <i>PLoS ONE</i> , 2014 , 9, e106810	3.7	10
535	The Impact of Genetic Polymorphisms on Neuroreceptor Imaging 2014 , 149-178		
534	Neuroimaging in Seasons and Winter Depression 2014 , 209-222		
533	Social Anxiety Disorder 2014 , 1-4		
532	A gap analysis for future supply of and demand for psychiatrists in Austria. <i>Journal of Mental Health Policy and Economics</i> , 2014 , 17, 9-18	1.3	1
531	Mixed, melancholic, and anxious features in depression: a cross-sectional study of sociodemographic and clinical correlates. <i>Annals of Clinical Psychiatry</i> , 2014 , 26, 243-53	1.4	4
530	Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013 , 44, 271-8	5.5	35
529	Influence of family history of major depression, bipolar disorder, and suicide on clinical features in patients with major depression and bipolar disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013 , 263, 93-103	5.1	20
528	Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. <i>Journal of Affective Disorders</i> , 2013 , 151, 209-19	6.6	51
527	Variation in the HTR1A and HTR2A genes and social adjustment in depressed patients. <i>Journal of Affective Disorders</i> , 2013 , 150, 649-52	6.6	9
526	Neuropsychiatric deep brain stimulation for translational neuroimaging. <i>NeuroImage</i> , 2013 , 79, 30-41	7.9	15

525	Testosterone in the brain: neuroimaging findings and the potential role for neuropsychopharmacology. <i>European Neuropsychopharmacology</i> , 2013 , 23, 79-88	1.2	55
524	P.2.b.044 Serotonin transporter association between dorsal raphe and ventral striatum is diminished in major depression. <i>European Neuropsychopharmacology</i> , 2013 , 23, S345	1.2	
523	The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. <i>American Journal of Psychiatry</i> , 2013 , 170, 1249-62	11.9	451
522	The best next drug in the course of generalized anxiety disorders: the "PN-GAD-algorithm". <i>International Journal of Psychiatry in Clinical Practice</i> , 2013 , 17, 78-89	2.4	5
521	Impact of electroconvulsive therapy on 5-HT1A receptor binding in major depression. <i>Molecular Psychiatry</i> , 2013 , 18, 1	15.1	6
520	An orally administered lavender oil preparation (Silexan) for anxiety disorder and related conditions: an evidence based review. <i>International Journal of Psychiatry in Clinical Practice</i> , 2013 , 17 Suppl 1, 15-22	2.4	33
519	Physical co-morbidity among treatment resistant vs. treatment responsive patients with major depressive disorder. <i>European Neuropsychopharmacology</i> , 2013 , 23, 895-901	1.2	20
518	RESCALE: Voxel-specific task-fMRI scaling using resting state fluctuation amplitude. <i>NeuroImage</i> , 2013 , 70, 80-8	7.9	27
517	Application of image-derived and venous input functions in major depression using [carbonyl-(11)C]WAY-100635. <i>Nuclear Medicine and Biology</i> , 2013 , 40, 371-7	2.1	33
516	The efficacy of agomelatine in previously-treated depressed patients. <i>European Neuropsychopharmacology</i> , 2013 , 23, 814-21	1.2	8
515	Social adjustment among treatment responder patients with mood disorders. <i>Journal of Affective Disorders</i> , 2013 , 150, 961-6	6.6	2
514	The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013 , 263, 385-91	5.1	12
513	Definitions and Predictors of Treatment-resistant Depression 2013 , 1-20		4
512	Treatment-resistant Depression 2013 , 21-41		1
511	Genetics of Treatment-resistant Depression 2013 , 43-90		1
510	Is There a Role for Switching Antidepressants in Treatment-resistant Depression? 2013 , 91-105		
509	Lithium, Thyroid Hormones and Further Augmentation Strategies in Treatment-resistant Depression 2013 , 129-157		2
508	The Role of Nonpharmacological Interventions in Treatment-resistant Depression 2013 , 159-182		2

507	The Role of Psychotherapy in the Management of Treatment-resistant Depression 2013 , 183-208		
506	The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2013 , 14, 154-219	3.8	284
505	A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline. <i>CNS Spectrums</i> , 2013 , 18, 163-70	1.8	25
504	Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control. <i>International Clinical Psychopharmacology</i> , 2013 , 28, 12-9	2.2	32
503	Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. <i>International Journal of Neuropsychopharmacology</i> , 2013 , 16, 557-74	5.8	101
502	The impact of adverse life events on clinical features and interaction with gene variants in mood disorder patients. <i>Psychopathology</i> , 2013 , 46, 384-9	3.4	9
501	Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET. <i>Molecular Psychiatry</i> , 2013 , 18, 93-100	15.1	84
500	The diagnosis and treatment of generalized anxiety disorder. <i>Deutsches A&#x0308;rztblatt International</i> , 2013 , 110, 300-9; quiz 310	2.5	33
499	Silexan (WSN 1265) vermindert begleitende depressive Symptome bei Patienten mit Angsterkrankungen. <i>Zeitschrift Fur Phytotherapie: Offizielles Organ Der Ges F Phytotherapie E V</i> , 2013 , 34,	0.1	3
498	Correspondence (reply): In reply. <i>Deutsches A&#x0308;rztblatt International</i> , 2013 , 110, 610-1	2.5	
497	Treatment resistance in severe unipolar depression: no association with psychotic or melancholic features. <i>Annals of Clinical Psychiatry</i> , 2013 , 25, 97-106	1.4	5
496	Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012 , 262, 13-22	5.1	17
495	Rediscovering trazodone for the treatment of major depressive disorder. <i>CNS Drugs</i> , 2012 , 26, 1033-49	6.7	109
494	P.4.002 Serotonin transporter ratio between raphe nuclei and projection areas predicts SSRI treatment response in major depression. <i>European Neuropsychopharmacology</i> , 2012 , 22, S85	1.2	
493	On the application of light therapy in German-speaking countries. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012 , 262, 501-5	5.1	12
492	The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder--a European multicenter study. <i>European Neuropsychopharmacology</i> , 2012 , 22, 259-66	1.2	32
491	European Group for the Study of Resistant Depression (GSRD)--where have we gone so far: review of clinical and genetic findings. <i>European Neuropsychopharmacology</i> , 2012 , 22, 453-68	1.2	91
490	Mortality and employment after in-patient opiate detoxification. <i>European Psychiatry</i> , 2012 , 27, 294-300		2

489	Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression. <i>European Psychiatry</i> , 2012 , 27, 114-28	6	27
488	Light-dependent alteration of serotonin-1A receptor binding in cortical and subcortical limbic regions in the human brain. <i>World Journal of Biological Psychiatry</i> , 2012 , 13, 413-22	3.8	43
487	The hidden third: improving outcome in treatment-resistant depression. <i>Journal of Psychopharmacology</i> , 2012 , 26, 587-602	4.6	49
486	A highly parallelized framework for computationally intensive MR data analysis. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2012 , 25, 313-20	2.8	13
485	Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression. <i>Neuroscience Letters</i> , 2012 , 516, 85-8	3.3	21
484	Effects of sunshine on suicide rates. <i>Comprehensive Psychiatry</i> , 2012 , 53, 535-9	7.3	47
483	Imaging treatment effects in depression. <i>Reviews in the Neurosciences</i> , 2012 , 23, 227-52	4.7	32
482	Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2012 , 16, 77-84	2.4	255
481	Combining image-derived and venous input functions enables quantification of serotonin-1A receptors with [carbonyl-11C]WAY-100635 independent of arterial sampling. <i>NeuroImage</i> , 2012 , 62, 199-206	7.9	14
480	Normative database of the serotonergic system in healthy subjects using multi-tracer PET. <i>NeuroImage</i> , 2012 , 63, 447-59	7.9	78
479	Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas. <i>NeuroImage</i> , 2012 , 63, 874-81	7.9	99
478	Serotonin-1A receptor binding is positively associated with gray matter volume -- a multimodal neuroimaging study combining PET and structural MRI. <i>NeuroImage</i> , 2012 , 63, 1091-8	7.9	21
477	Fully exploratory network independent component analysis of the 1000 functional connectomes database. <i>Frontiers in Human Neuroscience</i> , 2012 , 6, 301	3.3	46
476	Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012 , 262 Suppl 1, 1-48	5.1	93
475	Hyponatraemia during psychopharmacological treatment: results of a drug surveillance programme. <i>International Journal of Neuropsychopharmacology</i> , 2012 , 15, 739-48	5.8	51
474	Differential modulation of the default mode network via serotonin-1A receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 2619-24	11.5	92
473	Failure to replicate influence of GRIK4 and GNB3 polymorphisms on treatment outcome in major depression. <i>Neuropsychobiology</i> , 2012 , 65, 70-5	4	20
472	Actigraphic measurements in opioid detoxification with methadone or buprenorphine. <i>Journal of Clinical Psychopharmacology</i> , 2012 , 32, 75-82	1.7	12

471	Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program. <i>International Journal of Neuropsychopharmacology</i> , 2012 , 15, 449-57	5.8	28
470	Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder. <i>International Journal of Neuropsychopharmacology</i> , 2012 , 15, 715-25	5.8	7
469	Is dopamine neurotransmission altered in prodromal schizophrenia? A review of the evidence. <i>Current Pharmaceutical Design</i> , 2012 , 18, 1568-79	3.3	18
468	Clinical data in early intervention. <i>International Psychogeriatrics</i> , 2012 , 24 Suppl 1, S41-5	3.4	6
467	Database of MNI stereotactic coordinates for deep brain stimulation targets in neuropsychiatric disorders. <i>European Psychiatry</i> , 2011 , 26, 1149-1149	6	
466	The viennese psychiatric intensive care unit - therapeutic modalities. <i>European Psychiatry</i> , 2011 , 26, 1764-1764		
465	Antidepressant self-poisonings in iran. <i>European Psychiatry</i> , 2011 , 26, 1268-1268	6	
464	The viennese psychiatric intensive care unit - diagnostic distribution. <i>European Psychiatry</i> , 2011 , 26, 1763-1763		1
463	FC04-06 - Candidate gene association study of suicidality in treatment resistant MDD. <i>European Psychiatry</i> , 2011 , 26, 1833-1833	6	
462	JS03-01 - Diagnosis and Treatment of Depression in Europe. <i>European Psychiatry</i> , 2011 , 26, 2003-2003	6	
461	JS02-01 - Psychiatric intensive care. <i>European Psychiatry</i> , 2011 , 26, 1999-1999	6	
460	Antipsychotics in obsessive-compulsive disorder - an auspicious approach for treatment-resistant patients?. <i>European Psychiatry</i> , 2011 , 26, 1236-1236	6	
459	SS05-03 - Proven antidepressant efficacy of agomelatine against the full range of symptoms. <i>European Psychiatry</i> , 2011 , 26, 2179-2179	6	
458	Orbitofrontal hyperactivity in social anxiety disorder patients: An fmri study. <i>European Psychiatry</i> , 2011 , 26, 179-179	6	1
457	Reduced connectivity in the uncinate fiber tract between the frontal cortex and limbic subcortical areas in social phobia. <i>European Psychiatry</i> , 2011 , 26, 182-182	6	3
456	Biological alterations during remission of major depressive disorder. <i>European Psychiatry</i> , 2011 , 26, 633-633		
455	Are there structural brain changes following 10 days of SSRI administration investigated by voxel-based morphometry?. <i>European Psychiatry</i> , 2011 , 26, 913-913	6	
454	Increased functional coupling between basal ganglia and cingulate and prefrontal cortex during resting state conditions in remitted major depressive disorder. <i>European Psychiatry</i> , 2011 , 26, 915-915	6	

453	Cortisol plasma levels are associated with serotonin - 1A receptor binding in postmenopausal women. <i>European Psychiatry</i> , 2011 , 26, 933-933	6	
452	Efficacy of escitalopram compared to citalopram: a meta-analysis. <i>International Journal of Neuropsychopharmacology</i> , 2011 , 14, 261-8	5.8	26
451	Reduced resting-state functional connectivity between amygdala and orbitofrontal cortex in social anxiety disorder. <i>NeuroImage</i> , 2011 , 56, 881-9	7.9	289
450	Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in schizophrenic or schizoaffective patients. <i>European Psychiatry</i> , 2011 , 26, 1415-1415	6	1415
449	COMT and age at onset in mood disorders: a replication and extension study. <i>Neuroscience Letters</i> , 2011 , 498, 218-21	3.3	27
448	Psychosocial background in incarcerated adolescents from Austria, Turkey and former Yugoslavia. <i>Psychiatry Research</i> , 2011 , 185, 193-9	9.9	12
447	No influence of PTGS2 polymorphisms on response and remission to antidepressants in major depression. <i>Psychiatry Research</i> , 2011 , 188, 166-9	9.9	9
446	P.1.e.027 Serotonin -1A receptor binding in the dorsal raphe nucleus is associated with hippocampal grey matter volume. <i>European Neuropsychopharmacology</i> , 2011 , 21, S318-S319	1.2	
445	P.1.e.028 Resting -state functional connectivity of the raphe nuclei. <i>European Neuropsychopharmacology</i> , 2011 , 21, S319-S320	1.2	
444	Intensive care in psychiatry. <i>European Psychiatry</i> , 2011 , 26, 260-4	6	9
443	Improvement of the noradrenergic symptom cluster following treatment with milnacipran. <i>Neuropsychiatric Disease and Treatment</i> , 2011 , 7, 21-7	3.1	11
442	Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2011 , 26, 1-10	2.2	60
441	Switching antidepressant class does not improve response or remission in treatment-resistant depression. <i>Journal of Clinical Psychopharmacology</i> , 2011 , 31, 512-6	1.7	71
440	A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. <i>Journal of Affective Disorders</i> , 2011 , 128, 56-63	6.6	43
439	Phenomenology of psychotic mood disorders: lifetime and major depressive episode features. <i>Journal of Affective Disorders</i> , 2011 , 135, 241-50	6.6	21
438	The genetic blueprint of major depressive disorder: contributions of imaging genetics studies. <i>World Journal of Biological Psychiatry</i> , 2011 , 12, 474-88	3.8	24
437	General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011 , 261 Suppl 3, 207-45	5.1	29
436	Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study. <i>World Journal of Biological Psychiatry</i> , 2011 , 12, 364-75	3.8	34

435	FC29-05 - Season, sunlight, and brain serotonin function. <i>European Psychiatry</i> , 2011 , 26, 1981-1981	6	1
434	Treatment Resistance in Depression. <i>European Psychiatry</i> , 2011 , 26, 2022-2022	6	
433	Meta-analysis on the dissection table. <i>European Psychiatry</i> , 2011 , 26, 1240-1240	6	
432	SS06-01 - Are we getting the most out of combination therapy in the short-term and long-term treatment of mania?. <i>European Psychiatry</i> , 2011 , 26, 2181-2181	6	
431	FC07-06 - Differences in the modulatory role of escitalopram and citalopram revealed by effective connectivity analysis. <i>European Psychiatry</i> , 2011 , 26, 1851-1851	6	
430	Progesterone level predicts serotonin-1a receptor binding in the male human brain. <i>Neuroendocrinology</i> , 2011 , 94, 84-8	5.6	16
429	Meta-analysis: fact or fiction? How to interpret meta-analyses. <i>World Journal of Biological Psychiatry</i> , 2011 , 12, 188-200	3.8	38
428	Polymorphisms of the 5-HT2A receptor gene and clinical response to olanzapine in paranoid schizophrenia. <i>Neuropsychobiology</i> , 2011 , 64, 202-10	4	13
427	Bright-light therapy in the treatment of mood disorders. <i>Neuropsychobiology</i> , 2011 , 64, 152-62	4	153
426	Widespread methodological problems limit validity of meta-analytic results. <i>Psychotherapy and Psychosomatics</i> , 2011 , 80, 246; author reply 247-8	9.4	4
425	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. <i>World Journal of Biological Psychiatry</i> , 2011 , 12, 400-43	3.8	125
424	A comparison of the Major Depression Inventory (MDI) and the Beck Depression Inventory (BDI) in severely depressed patients. <i>International Journal of Psychiatry in Clinical Practice</i> , 2011 , 15, 56-61	2.4	29
423	The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence. <i>World Journal of Biological Psychiatry</i> , 2011 , 12, 160-87	3.8	73
422	Sonstige biologische Therapieverfahren □Theoretische und empirische Grundlagen sowie klinische Anwendungsprinzipien 2011 , 767-805		
421	Psychopharmakotherapie □Klinisch-empirische Grundlagen 2011 , 731-766		2
420	Milnacipran: a unique antidepressant?. <i>Neuropsychiatric Disease and Treatment</i> , 2010 , 6, 23-31	3.1	18
419	Pharmacotherapy Update: Pregabalin in the Treatment of Generalized Anxiety Disorder. <i>Clinical Medicine Insights Therapeutics</i> , 2010 , 2, CMT.S1103	0	4
418	Dysbindin gene (DTNBP1) in major depressive disorder (MDD) patients: lack of association with clinical phenotypes. <i>World Journal of Biological Psychiatry</i> , 2010 , 11, 985-90	3.8	3

417	Escitalopram enhances the association of serotonin-1A autoreceptors to heteroreceptors in anxiety disorders. <i>Journal of Neuroscience</i> , 2010 , 30, 14482-9	6.6	39
416	Interaction between serotonin 5-HT _{2A} receptor gene and dopamine transporter (DAT1) gene polymorphisms influences personality trait of persistence in Austrian Caucasians. <i>World Journal of Biological Psychiatry</i> , 2010 , 11, 417-24	3.8	12
415	Acute psychotropic effects of oral cannabis extract with a defined content of Delta9-tetrahydrocannabinol (THC) in healthy volunteers. <i>Pharmacopsychiatry</i> , 2010 , 43, 24-32	2	20
414	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. <i>World Journal of Biological Psychiatry</i> , 2010 , 11, 81-109	3.8	256
413	Hypothalamic serotonin-1A receptor binding measured by PET predicts the plasma level of dehydroepiandrosterone sulfate in healthy women. <i>Neuroscience Letters</i> , 2010 , 476, 161-5	3.3	13
412	Reward and the serotonergic system. <i>Neuroscience</i> , 2010 , 166, 1023-35	3.9	189
411	Efficacy and tolerability of Hypericum extract for the treatment of mild to moderate depression. <i>European Neuropsychopharmacology</i> , 2010 , 20, 747-65	1.2	94
410	Regional sex differences in grey matter volume are associated with sex hormones in the young adult human brain. <i>NeuroImage</i> , 2010 , 49, 1205-12	7.9	118
409	Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study. <i>NeuroImage</i> , 2010 , 49, 1161-70	7.9	95
408	Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder. <i>World Journal of Biological Psychiatry</i> , 2010 , 11, 36-44	3.8	21
407	Better tolerability of St. John's wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression. <i>International Clinical Psychopharmacology</i> , 2010 , 25, 204-13	2.2	35
406	Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of sub-syndromal anxiety disorder: a randomized, double-blind, placebo controlled trial. <i>International Clinical Psychopharmacology</i> , 2010 , 25, 277-87	2.2	100
405	Cortisol plasma levels in social anxiety disorder patients correlate with serotonin-1A receptor binding in limbic brain regions. <i>International Journal of Neuropsychopharmacology</i> , 2010 , 13, 1129-43	5.8	42
404	Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study. <i>International Clinical Psychopharmacology</i> , 2010 , 25, 297-301 ²	3.2	12
403	5HT _{1A} and 5HT _{2A} receptor genes in treatment response phenotypes in major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2010 , 25, 228-31	2.2	34
402	The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study. <i>International Clinical Psychopharmacology</i> , 2010 , 25, 218-27	2.2	44
401	Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. <i>Journal of Clinical Psychiatry</i> , 2010 , 71, 109-20	4.6	179
400	The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010 , 260, 59-68 ^{5.1}	5.1	24

399	Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder - evidence from clinical trials. <i>Wiener Medizinische Wochenschrift</i> , 2010 , 160, 547-56	2.9	46
398	Psycho-pharmacotherapy for anxiety and obsessive-compulsive disorder: the issue of prolonged barbiturate retention. <i>Current Medical Research and Opinion</i> , 2009 , 25, 2281-5	2.5	3
397	Self-poisonings with tricyclic antidepressants and selective serotonin reuptake inhibitors in Tehran, Iran. <i>World Journal of Biological Psychiatry</i> , 2009 , 10, 302-12	3.8	2
396	How to improve adherence to antipsychotic treatment: Outcomes of the IMPROVING PATIENT OUTCOMES in psychiatry (IMPACT) Berlin 2009 meeting workshop. <i>International Journal of Psychiatry in Clinical Practice</i> , 2009 , 13, 245-52	2.4	4
395	Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol—a double-blind multicenter trial. <i>Journal of Psychiatric Research</i> , 2009 , 43, 702-10	5.2	27
394	Therapeutic effects of escitalopram and reboxetine in seasonal affective disorder: a pooled analysis. <i>Journal of Psychiatric Research</i> , 2009 , 43, 792-7	5.2	17
393	Aggression is related to frontal serotonin-1A receptor distribution as revealed by PET in healthy subjects. <i>Human Brain Mapping</i> , 2009 , 30, 2558-70	5.9	69
392	The psychiatrist confronted with a fibromyalgia patient. <i>Human Psychopharmacology</i> , 2009 , 24 Suppl 1, S25-30	2.3	6
391	Influence of escitalopram treatment on 5-HT 1A receptor binding in limbic regions in patients with anxiety disorders. <i>Molecular Psychiatry</i> , 2009 , 14, 1040-50	15.1	76
390	Sex-specific predictors of criminal recidivism in a representative sample of incarcerated youth. <i>Comprehensive Psychiatry</i> , 2009 , 50, 400-7	7.3	46
389	The serotonin-1A receptor in anxiety disorders. <i>Biological Psychiatry</i> , 2009 , 66, 627-35	7.9	240
388	Pharmacological Properties of Psychopharmaca in Relationship to their Clinical Indications. <i>European Psychiatry</i> , 2009 , 24, 1-1	6	
387	Neuroimaging Findings and Diagnosis. <i>European Psychiatry</i> , 2009 , 24, 1-1	6	
386	The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. <i>World Journal of Biological Psychiatry</i> , 2009 , 10, 85-116	3.8	251
385	Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action. <i>World Journal of Biological Psychiatry</i> , 2009 , 10, 117-26	3.8	62
384	Superiority of escitalopram to paroxetine in the treatment of depression. <i>European Neuropsychopharmacology</i> , 2009 , 19, 229-37	1.2	22
383	Lateralization of the serotonin-1A receptor distribution in language areas revealed by PET. <i>NeuroImage</i> , 2009 , 45, 598-605	7.9	64
382	P.1.16 Serotonin-1A receptor binding potential in dorsal raphe nuclei predicts orbitofrontal reactivity in healthy subjects. <i>European Neuropsychopharmacology</i> , 2009 , 19, S15-S16	1.2	1

381	P.2.c.002 Serotonin or noradrenalin reuptake inhibition in seasonal affective disorder: escitalopram versus reboxetine. <i>European Neuropsychopharmacology</i> , 2009 , 19, S404	1.2	1
380	Ranking antidepressants. <i>Lancet, The</i> , 2009 , 373, 1760-1; author reply 1761-2	4.0	11
379	Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. <i>International Clinical Psychopharmacology</i> , 2009 , 24, 119-25	2.2	44
378	Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. <i>International Clinical Psychopharmacology</i> , 2009 , 24, 250-6	2.2	57
377	The role of pharmacogenetics in the treatment of depression and anxiety disorders. <i>International Clinical Psychopharmacology</i> , 2009 , 24, 277-88	2.2	51
376	Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. <i>International Clinical Psychopharmacology</i> , 2009 , 24, 87-96	2.2	68
375	Drug treatment of seasonal affective disorder 2009 , 281-296		5
374	Maintenance pharmacotherapy in schizophrenia. <i>Medical Psychiatry</i> , 2009 , 174-184		
373	Social anxiety disorder: epidemiology, biology and treatment. <i>Psychiatria Danubina</i> , 2009 , 21, 533-42	1.8	11
372	CREB-regulated diurnal activity patterns are not indicative for depression-like symptoms in mice and men. <i>Medical Hypotheses</i> , 2008 , 70, 117-21	3.8	0
371	Humoral phototransduction: light transportation in the blood, and possible biological effects. <i>Medical Hypotheses</i> , 2008 , 71, 314-7	3.8	9
370	S.07.04 Progesterone and estradiol plasma levels modulate serotonin-1A binding in the human brain. <i>European Neuropsychopharmacology</i> , 2008 , 18, S168	1.2	
369	Multimodal imaging of human early visual cortex by combining functional and molecular measurements with fMRI and PET. <i>NeuroImage</i> , 2008 , 41, 204-11	7.9	32
368	A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. <i>European Neuropsychopharmacology</i> , 2008 , 18, 122-7	1.2	47
367	Do we need another atypical antipsychotic?. <i>European Neuropsychopharmacology</i> , 2008 , 18 Suppl 3, S146-52		7
366	Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial. <i>European Neuropsychopharmacology</i> , 2008 , 18, 803-13	1.2	35
365	Neurobiological and clinical effects of the antidepressant tianeptine. <i>CNS Drugs</i> , 2008 , 22, 15-26	6.7	174
364	Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. <i>Neuropsychopharmacology</i> , 2008 , 33, 1633-41	8.7	76

363	Enhanced serotonin transporter function during depression in seasonal affective disorder. <i>Neuropsychopharmacology</i> , 2008 , 33, 1503-13	8.7	75
362	Treatment of seasonal affective disorder with duloxetine: an open-label study. <i>Pharmacopsychiatry</i> , 2008 , 41, 100-5	2	22
361	Everyday problems in treating depression: focus on SNRIs. Introduction. <i>CNS Spectrums</i> , 2008 , 13, 4	1.8	1
360	Efficacy of St. John® wort extract WS 5570 in acute treatment of mild depression: a reanalysis of data from controlled clinical trials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008 , 258, 59-63	5.1	26
359	The serotonin-1A receptor distribution in healthy men and women measured by PET and [carbonyl-11C]WAY-100635. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008 , 35, 2159-68	8.8	50
358	Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008 , 258 Suppl 3, 3-23	5.1	64
357	Nichtpharmakologische somatische Therapien 2008 , 727-750		
356	Sonstige biologische Therapieverfahren (EKT, Schlafentzugsbehandlung, Lichttherapie, TMS, VNS) [Theoretische und empirische Grundlagen sowie klinische Anwendungsprinzipien 2008 , 669-690		
355	Psychopharmakotherapie [Klinisch-empirische Grundlagen 2008 , 627-667		0
354	Reduced serotonin-1A receptor binding in social anxiety disorder. <i>Biological Psychiatry</i> , 2007 , 61, 1081-97.9		232
353	Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. <i>International Journal of Neuropsychopharmacology</i> , 2007 , 10, 661-73	5.8	162
352	Three circadian clock genes Per2, Arntl, and Npas2 contribute to winter depression. <i>Annals of Medicine</i> , 2007 , 39, 229-38	1.5	193
351	Escitalopram in a working population: results from an observational study of 2378 outpatients in Austria. <i>Human Psychopharmacology</i> , 2007 , 22, 245-51	2.3	7
350	Agomelatine in the treatment of seasonal affective disorder. <i>Psychopharmacology</i> , 2007 , 190, 575-9	4.7	86
349	Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study. <i>Psychopharmacology</i> , 2007 , 191, 333-9	4.7	53
348	Placebo controlled continuation treatment with Hypericum extract WS 5570 after recovery from a mild or moderate depressive episode. <i>Wiener Medizinische Wochenschrift</i> , 2007 , 157, 362-6	2.9	6
347	Serum lipid levels in seasonal affective disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007 , 257, 197-202	5.1	5
346	Season of birth in siblings of patients with seasonal affective disorder. A test of the parental conception habits hypothesis. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007 , 257, 378-82	5.1	8

345	Management of acutely ill patients in the hospital setting: focus on quetiapine. <i>International Journal of Psychiatry in Clinical Practice</i> , 2007 , 11, 61-72	2.4	1
344	Escitalopram in seasonal affective disorder: results of an open trial. <i>Pharmacopsychiatry</i> , 2007 , 40, 20-4	2	20
343	Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. <i>International Clinical Psychopharmacology</i> , 2007 , 22, 283-91	2.2	94
342	Which antidepressants have demonstrated superior efficacy? A review of the evidence. <i>International Clinical Psychopharmacology</i> , 2007 , 22, 323-9	2.2	103
341	Binding kinetics of ¹²³ I[ADAM] in healthy controls: a selective SERT radioligand. <i>International Journal of Neuropsychopharmacology</i> , 2007 , 10, 211-8	5.8	6
340	Quetiapine in combination with citalopram in patients with unipolar psychotic depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007 , 31, 242-7	5.5	14
339	Striatal D(2) receptor occupancy in bipolar patients treated with olanzapine. <i>European Neuropsychopharmacology</i> , 2007 , 17, 102-7	1.2	16
338	Additional support for linkage of schizophrenia and bipolar disorder to chromosome 3q29. <i>European Neuropsychopharmacology</i> , 2007 , 17, 501-5	1.2	8
337	Current issues in bipolar disorder: a critical review. <i>European Neuropsychopharmacology</i> , 2007 , 17, 687-95	2	45
336	Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial. <i>European Psychiatry</i> , 2007 , 22, 195-202	6	16
335	Prinzipien der Psychopharmakotherapie 2007 , 1474-1481		
334	Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, 1062-70	4.6	313
333	In vivo imaging of serotonin transporter occupancy by means of SPECT and [¹²³ I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. <i>Psychopharmacology</i> , 2006 , 188, 263-72	4.7	63
332	Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]. <i>BMC Medicine</i> , 2006 , 4, 14	11.4	61
331	Trazodone-induced cardiac arrhythmias: a report of two cases. <i>Human Psychopharmacology</i> , 2006 , 21, 61-2	2.3	14
330	Anger attacks in seasonal affective disorder. <i>International Journal of Neuropsychopharmacology</i> , 2006 , 9, 215-9	5.8	10
329	Validation of a simplified definition of anger attacks. <i>Psychotherapy and Psychosomatics</i> , 2006 , 75, 103-6	9.4	10
328	Typical neuroleptics vs. atypical antipsychotics in the treatment of acute mania in a natural setting. <i>International Journal of Neuropsychopharmacology</i> , 2006 , 9, 529-37	5.8	5

327	Escitalopram in the long-term treatment of major depressive disorder in elderly patients. <i>Neuropsychobiology</i> , 2006 , 54, 152-9	4	18
326	Intravenous mirtazapine is safe and effective in the treatment of depressed inpatients. <i>Neuropsychobiology</i> , 2006 , 53, 83-7	4	4
325	Addressing the limitations of the CATIE study. <i>World Journal of Biological Psychiatry</i> , 2006 , 7, 126-7	3.8	12
324	Treatment of seasonal affective disorder. <i>Expert Review of Neurotherapeutics</i> , 2006 , 6, 1039-48	4.3	35
323	Anxiety disorders: under-diagnosed and insufficiently treated. <i>International Journal of Psychiatry in Clinical Practice</i> , 2006 , 10 Suppl 1, 3-9	2.4	37
322	The Korean Medication Algorithm for Major Depressive Disorder (KMA-MDD): Report of the Korean Society of Depressive and Bipolar Disorders. <i>International Journal of Psychiatry in Clinical Practice</i> , 2006 , 10, 186-94	2.4	14
321	Optimisation of long-term treatment in schizophrenia: treating the true spectrum of symptoms. <i>European Neuropsychopharmacology</i> , 2006 , 16 Suppl 3, S135-41	1.2	17
320	Tardive Dyskinesia: analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America. <i>Schizophrenia Research</i> , 2006 , 81, 139-43	3.6	20
319	Case report: intestinal atonia as an unusual symptom of malignant catatonia responsive to electroconvulsive therapy. <i>Schizophrenia Research</i> , 2006 , 84, 178-9	3.6	6
318	Gender-specific symptoms of depression and anger attacks. <i>The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender</i> , 2006 , 3, 19-24		22
317	Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. <i>International Clinical Psychopharmacology</i> , 2006 , 21, 105-10	2.2	54
316	Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. <i>Journal of Clinical Psychiatry</i> , 2006 , 67, 771-82	4.6	151
315	Anger attacks in depression--evidence for a male depressive syndrome. <i>Psychotherapy and Psychosomatics</i> , 2005 , 74, 303-7	9.4	107
314	No association of clock gene T3111C polymorphism and affective disorders. <i>European Neuropsychopharmacology</i> , 2005 , 15, 51-5	1.2	38
313	Escitalopram in the Treatment of Depressed Elderly Patients. <i>American Journal of Geriatric Psychiatry</i> , 2005 , 13, 884-891	6.5	84
312	Recurrent brief depression revisited. <i>International Review of Psychiatry</i> , 2005 , 17, 63-70	3.6	18
311	Psychosis as a possible side-effect of treatment with glatiramer acetate. <i>International Journal of Neuropsychopharmacology</i> , 2005 , 8, 487-8	5.8	4
310	A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. <i>Current Medical Research and Opinion</i> , 2005 , 21, 1139-46	2.5	33

309	Effect of intravenous magnesium sulphate in reducing irritability and restlessness in pure and polysubstance opiate detoxification. <i>Psychiatry Research</i> , 2005 , 135, 53-63	9.9	6
308	Actigraphy in patients with seasonal affective disorder and healthy control subjects treated with light therapy. <i>Biological Psychiatry</i> , 2005 , 58, 331-6	7.9	55
307	Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. <i>British Journal of Psychiatry</i> , 2005 , 186, 222-6	5.4	118
306	Pharmacotherapy of seasonal affective disorder. <i>CNS Spectrums</i> , 2005 , 10, 664-9; quiz 672	1.8	12
305	Is SAD Lost to SAD?. <i>CNS Spectrums</i> , 2005 , 10, 622	1.8	
304	White matter hyperintensities and chronicity of depression. <i>Journal of Psychiatric Research</i> , 2005 , 39, 285-93	5.2	49
303	A Cys 23-Ser 23 substitution in the 5-HT(2C) receptor gene influences body weight regulation in females with seasonal affective disorder: an Austrian-Canadian collaborative study. <i>Journal of Psychiatric Research</i> , 2005 , 39, 561-7	5.2	7
302	Placebo-controlled trials in major depression are necessary and ethically justifiable: how to improve the communication between researchers and ethical committees. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005 , 255, 258-60	5.1	18
301	Clinical efficacy in depression 2005 , 123-131		
300	Escitalopram in the treatment of depressed elderly patients. <i>American Journal of Geriatric Psychiatry</i> , 2005 , 13, 884-91	6.5	28
299	Prinzipien der Psychopharmakotherapie 2005 , 1311-1317		
298	Rezidivierende kurze depressive Episoden und Rapid Cycling 2005 , 503-510		
297	Evaluation of the Two-Way Communication Checklist as a clinical intervention. Results of a multinational, randomised controlled trial. <i>British Journal of Psychiatry</i> , 2004 , 184, 79-83	5.4	46
296	Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. <i>Current Medical Research and Opinion</i> , 2004 , 20, 869-78	2.5	31
295	Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression. <i>Annals of Pharmacotherapy</i> , 2004 , 38, 954-60	2.9	26
294	Brightening depression. <i>Science</i> , 2004 , 303, 467-9	33.3	58
293	A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. <i>International Journal of Neuropsychopharmacology</i> , 2004 , 7, 507-22	5.8	60
292	Possible linkage of schizophrenia and bipolar affective disorder to chromosome 3q29; a follow-up. <i>Journal of Psychiatric Research</i> , 2004 , 38, 357-64	5.2	16

291	Gender differences in the psychopathology of depressed inpatients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004 , 254, 209-14	5.1	31
290	A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder. <i>Psychopharmacology</i> , 2004 , 171, 390-7	4.7	57
289	Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. <i>Depression and Anxiety</i> , 2004 , 20, 44-7	8.4	29
288	Escitalopram in the treatment of social anxiety disorder: analysis of efficacy for different clinical subgroups and symptom dimensions. <i>Depression and Anxiety</i> , 2004 , 20, 175-81	8.4	34
287	Guided self-help versus cognitive-behavioral group therapy in the treatment of bulimia nervosa. <i>International Journal of Eating Disorders</i> , 2004 , 35, 522-37	6.3	80
286	Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after successful acute treatment of mild to moderate depression--rationale and study design. <i>International Journal of Methods in Psychiatric Research</i> , 2004 , 13, 176-83	4.3	5
285	Unique mechanism of action for escitalopram: does it hold the promise?. <i>International Journal of Psychiatry in Clinical Practice</i> , 2004 , 8 Suppl 1, 15-8	2.4	4
284	The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. <i>World Journal of Biological Psychiatry</i> , 2004 , 5, 120-35	3.8	104
283	Serotonin transporter promoter gene polymorphic region (5-HTTLPR) and personality in female patients with seasonal affective disorder and in healthy controls. <i>European Neuropsychopharmacology</i> , 2004 , 14, 53-8	1.2	16
282	Bright light therapy in seasonal affective disorder--does it suffice?. <i>European Neuropsychopharmacology</i> , 2004 , 14, 347-51	1.2	26
281	ECNP Consensus Meeting, March 2003. Guidelines for the investigation of efficacy in social anxiety disorder. <i>European Neuropsychopharmacology</i> , 2004 , 14, 425-33	1.2	9
280	Changing aspects of psychiatric inpatient treatment. A census investigation in five European countries. <i>European Psychiatry</i> , 2004 , 19, 483-8	6	29
279	Seasonal affective disorder and the G-protein beta-3-subunit C825T polymorphism. <i>Biological Psychiatry</i> , 2004 , 55, 317-9	7.9	22
278	Biophotons, microtubules and CNS, is our brain a "holographic computer"?. <i>Medical Hypotheses</i> , 2004 , 62, 169-72	3.8	16
277	Therapy of treatment resistant depression: focus on the management of TRD with atypical antipsychotics. <i>CNS Spectrums</i> , 2004 , 9, 823-32	1.8	16
276	Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia. <i>International Clinical Psychopharmacology</i> , 2004 , 19, 281-9	2.2	19
275	Menstrual disturbances a rare side-effect of bright-light therapy. <i>International Journal of Neuropsychopharmacology</i> , 2004 , 7, 239-40	5.8	8
274	A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. <i>Journal of Clinical Psychiatry</i> , 2004 , 65, 432-41	4.6	365

273	Seasonality of birth in seasonal affective disorder. <i>Journal of Clinical Psychiatry</i> , 2004 , 65, 1389-93	4.6	26
272	Demenzen 2004 , 250-280		
271	Diagnose und Behandlung der subsyndromalen SAD 2004 , 33-40		
270	Epidemiologie der saisonal abhängigen Depression (SAD) und ihrer subsyndromalen Form (S-SAD) 2004 , 23-32		
269	Prolaktin 2004 , 88-108		
268	Bipolare affektive Störungen 2004 , 189-222		
267	Pharmakodynamik 2004 , 368-376		
266	International Consensus Group on Bipolar I Depression Treatment Guidelines. <i>Journal of Clinical Psychiatry</i> , 2004 , 65, 571-9	4.6	28
265	Circadian clock-related polymorphisms in seasonal affective disorder and their relevance to diurnal preference. <i>Neuropsychopharmacology</i> , 2003 , 28, 734-9	8.7	276
264	Quetiapine in a delusional depressed elderly patient: no EPS and a favourable outcome. <i>International Journal of Neuropsychopharmacology</i> , 2003 , 6, 199-200	5.8	0
263	Quetiapine in the treatment of borderline personality disorder. <i>World Journal of Biological Psychiatry</i> , 2003 , 4, 42-4	3.8	26
262	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. <i>World Journal of Biological Psychiatry</i> , 2003 , 4, 5-13	3.8	124
261	Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2003 , 6, 325-37	5.8	226
260	Recurrent brief depressive disorder reinvestigated: a community sample of adolescents and young adults. <i>Psychological Medicine</i> , 2003 , 33, 407-18	6.9	28
259	The serotonin transporter promoter repeat length polymorphism, seasonal affective disorder and seasonality. <i>Psychological Medicine</i> , 2003 , 33, 785-92	6.9	33
258	Quantification of metabolic differences in the frontal brain of depressive patients and controls obtained by 1H-MRS at 3 Tesla. <i>Investigative Radiology</i> , 2003 , 38, 403-8	10.1	122
257	Sonstige biologische Therapieverfahren (EKT, TMS, VNS, Schlafentzugsbehandlung, Lichttherapie): theoretische und empirische Grundlagen sowie klinische Anwendungsprinzipien 2003 , 610-629		
256	Relationship between power spectra of the awake EEG and psychomotor activity patterns measured by short-term actigraphy. <i>Neuropsychobiology</i> , 2003 , 48, 176-81	4	2

255	Placebo-controlled studies in depression: necessary, ethical and feasible. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2003 , 253, 22-8	5.1	48
254	Cognitive effects and antipsychotic treatment. <i>Psychoneuroendocrinology</i> , 2003 , 28 Suppl 1, 27-38	5	52
253	A polymorphism (5-HTTLPR) in the serotonin transporter promoter gene is associated with DSM-IV depression subtypes in seasonal affective disorder. <i>Molecular Psychiatry</i> , 2003 , 8, 942-6	15.1	84
252	Effects of tryptophan depletion and catecholamine depletion on immune parameters in patients with seasonal affective disorder in remission with light therapy. <i>Biological Psychiatry</i> , 2003 , 53, 332-7	7.9	15
251	Milnacipran in the treatment of bulimia nervosa: a report of 16 cases. <i>European Neuropsychopharmacology</i> , 2003 , 13, 73-9	1.2	17
250	Clonazepam in the long-term treatment of patients with unipolar depression, bipolar and schizoaffective disorder. <i>European Neuropsychopharmacology</i> , 2003 , 13, 129-34	1.2	28
249	Issues in the treatment of bipolar disorder. <i>European Neuropsychopharmacology</i> , 2003 , 13 Suppl 2, S37-42	4.2	14
248	C825T polymorphism in the G protein beta3-subunit gene is associated with seasonal affective disorder. <i>Biological Psychiatry</i> , 2003 , 54, 682-6	7.9	35
247	Treatment of depressive symptoms with quetiapine. <i>Expert Review of Neurotherapeutics</i> , 2003 , 3, 417-23	4.3	3
246	Psychiatrische Erkrankungen 2003 , 1265-1384		
245	Notfälle in der Psychiatrie 2003 , 429-442		
244	Paranoid delusions and hallucinations and bright light therapy in Alzheimer® disease. <i>International Journal of Geriatric Psychiatry</i> , 2002 , 17, 1071-2	3.9	9
243	Managing reboxetine-associated urinary hesitancy in a patient with major depressive disorder: a case study. <i>Psychopharmacology</i> , 2002 , 159, 445-6	4.7	6
242	Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. <i>Psychopharmacology</i> , 2002 , 162, 42-9	4.7	65
241	St John® wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. <i>Psychopharmacology</i> , 2002 , 164, 294-300	4.7	72
240	Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in mildly to moderately depressed out-patients. A meta-analysis of data from three randomized, placebo-controlled trials. <i>Psychopharmacology</i> , 2002 , 164, 301-8	4.7	35
239	Intravenous antidepressant treatment: focus on citalopram. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2002 , 252, 105-9	5.1	17
238	Changes of clinical pattern in seasonal affective disorder (SAD) over time in a German-speaking sample. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2002 , 252, 54-62	5.1	29

237	2-COM: an instrument to facilitate patient-professional communication in routine clinical practice. <i>Acta Psychiatrica Scandinavica</i> , 2002 , 106, 446-52	6.5	19
236	Opioid addiction changes cerebral blood flow symmetry. <i>Neuropsychobiology</i> , 2002 , 45, 67-73	4	44
235	Successful treatment of recurrent brief depression with reboxetine -- a single case analysis. <i>Pharmacopsychiatry</i> , 2002 , 35, 75-6	2	12
234	Sertindole: safety and tolerability profile. <i>International Journal of Psychiatry in Clinical Practice</i> , 2002 , 6, 27-32	2.4	8
233	Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression. <i>Archives of General Psychiatry</i> , 2002 , 59, 613-20		165
232	Maintenance treatment in depression: the role of pharmacological and psychological treatment. <i>Current Opinion in Psychiatry</i> , 2002 , 15, 63-68	4.9	11
231	Optimizing antidepressant treatment: are two actions better than one?. <i>International Clinical Psychopharmacology</i> , 2002 , 17, 1	2.2	23
230	Genome scan for susceptibility loci for schizophrenia and bipolar disorder. <i>Biological Psychiatry</i> , 2002 , 52, 40-52	7.9	89
229	Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette disorder--implications for psychopharmacology. <i>World Journal of Biological Psychiatry</i> , 2002 , 3, 133-46	3.8	70
228	A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression. <i>European Psychiatry</i> , 2002 , 17 Suppl 3, 331-40	6	116
227	Intravenous mirtazapine in the treatment of depressed inpatients. <i>European Neuropsychopharmacology</i> , 2002 , 12, 57-60	1.2	9
226	Successful treatment of reboxetine-induced urinary hesitancy with tamsulosin. <i>European Neuropsychopharmacology</i> , 2002 , 12, 119-22	1.2	13
225	Role of family history and 5-HTTLPR polymorphism in female seasonal affective disorder patients with and without premenstrual dysphoric disorder. <i>European Neuropsychopharmacology</i> , 2002 , 12, 129-34 ²	1.2	31
224	The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. <i>European Neuropsychopharmacology</i> , 2002 , 12, 461-75	1.2	138
223	Rapid transcranial magnetic stimulation (r-TMS): A novel treatment option for seasonal affective disorder (SAD)?. <i>European Neuropsychopharmacology</i> , 2002 , 12, 252	1.2	2
222	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. <i>World Journal of Biological Psychiatry</i> , 2002 , 3, 171-99	3.8	133
221	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. <i>World Journal of Biological Psychiatry</i> , 2002 , 3, 115-24	3.8	139
220	Physical signs in psychiatry: a step towards evidence-based medicine. <i>International Journal of Psychiatry in Clinical Practice</i> , 2002 , 6, 69-72	2.4	1

219	Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. <i>Journal of Clinical Psychiatry</i> , 2002 , 63, 826-37	4.6	133
218	A longitudinal view of triggers and thresholds of suicidal behavior in depression. <i>Journal of Clinical Psychiatry</i> , 2002 , 63, 866-73	4.6	20
217	Aminprurorsoren 2002 , 627-649		
216	Serotonin-selektive Antidepressiva(SSRI, DSA) 2002 , 223-363		
215	Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. <i>Archives of General Psychiatry</i> , 2002 , 59, 514-20		115
214	Atypical antipsychotics in mood disorders. <i>International Clinical Psychopharmacology</i> , 2002 , 17 Suppl 3, S1-10	2.2	1
213	Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia. <i>International Clinical Psychopharmacology</i> , 2002 , 17 Suppl 4, S19-26	2.2	2
212	Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. <i>International Clinical Psychopharmacology</i> , 2001 , 16, 179-87 ^{2.2}		25
211	Monoaminergic function in the pathogenesis of seasonal affective disorder. <i>International Journal of Neuropsychopharmacology</i> , 2001 , 4, 409-20	5.8	51
210	In vivo (123)I IBZM SPECT imaging of striatal dopamine 2 receptor occupancy in schizophrenic patients. <i>Psychopharmacology</i> , 2001 , 157, 236-42	4.7	14
209	CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. <i>Acta Psychiatrica Scandinavica</i> , 2001 , 104, 173-92	6.5	285
208	Prevalence of premenstrual dysphoric disorder in female patients with seasonal affective disorder. <i>Journal of Affective Disorders</i> , 2001 , 63, 239-42	6.6	39
207	Serotonin 5-HT1A receptor binding potential declines with age as measured by [11C]WAY-100635 and PET. <i>Neuropsychopharmacology</i> , 2001 , 24, 522-30	8.7	93
206	Inverse relationship between serotonin 5-HT(1A) receptor binding and anxiety: a [(11)C]WAY-100635 PET investigation in healthy volunteers. <i>American Journal of Psychiatry</i> , 2001 , 158, 1326-8	11.9	120
205	Hypericum perforatum--a review of clinical studies. <i>Pharmacopsychiatry</i> , 2001 , 34 Suppl 1, S51-5	2	62
204	Reboxetine in seasonal affective disorder: an open trial. <i>European Neuropsychopharmacology</i> , 2001 , 11, 1-5	1.2	23
203	No change in striatal dopamine re-uptake site density in psychotropic drug naive and in currently treated Tourette disorder patients: a [(123)I]-beta-CIT SPECT-study. <i>European Neuropsychopharmacology</i> , 2001 , 11, 69-74	1.2	45
202	Different fatal toxicity of neuroleptics identified by autopsy. <i>European Neuropsychopharmacology</i> , 2001 , 11, 117-24	1.2	20

201	Panic disorder: the place of benzodiazepines and selective serotonin reuptake inhibitors. <i>European Neuropsychopharmacology</i> , 2001 , 11, 307-21	1.2	35
200	Quetiapine: efficacy and tolerability in schizophrenia. <i>European Neuropsychopharmacology</i> , 2001 , 11 Suppl 4, S405-13	1.2	22
199	[123I] beta-CIT and single photon emission computed tomography reveal reduced brain serotonin transporter availability in bulimia nervosa. <i>Biological Psychiatry</i> , 2001 , 49, 326-32	7.9	123
198	No evidence for in vivo regulation of midbrain serotonin transporter availability by serotonin transporter promoter gene polymorphism. <i>Biological Psychiatry</i> , 2001 , 50, 8-12	7.9	112
197	The effects of light therapy on mini-mental state examination scores in demented patients. <i>Biological Psychiatry</i> , 2001 , 50, 725-7	7.9	64
196	Study of family history in seasonal affective disorder. <i>Neuropsychobiology</i> , 2001 , 44, 65-9	4	4
195	Topiramate as a mood stabilizer. <i>International Clinical Psychopharmacology</i> , 2001 , 16, 295-8	2.2	11
194	Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study. <i>International Clinical Psychopharmacology</i> , 2001 , 16, 189-96	2.2	21
193	Inverse relation between stimulus intensity and seizure duration: implications for ECT procedure. <i>Journal of ECT</i> , 2001 , 17, 102-8	2	27
192	Zotepine in the treatment of acute hospitalized schizophrenic episodes. <i>International Clinical Psychopharmacology</i> , 2001 , 16, 163-8	2.2	6
191	Fluoxetine treatment in patients with recurrent brief depression. <i>International Clinical Psychopharmacology</i> , 2001 , 16, 221-6	2.2	15
190	Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. <i>International Clinical Psychopharmacology</i> , 2001 , 16, 75-86	2.2	117
189	A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer® disease. <i>International Clinical Psychopharmacology</i> , 2001 , 16, 253-63	2.2	36
188	Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder. <i>International Clinical Psychopharmacology</i> , 2001 , 16, 357-61	2.2	46
187	Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls. <i>Psychological Medicine</i> , 2001 , 31, 1467-73	6.9	85
186	St John® wort extract: an effective and well-tolerated antidepressant. <i>Primary Care and Community Psychiatry</i> , 2001 , 7, 39-42		4
185	Occurrence of mirtazapine-induced delirium in organic brain disorder. <i>International Clinical Psychopharmacology</i> , 2000 , 15, 239-43	2.2	11
184	Effective open-label treatment of tourette® disorder with olanzapine. <i>International Clinical Psychopharmacology</i> , 2000 , 15, 23-8	2.2	48

183	Non-association of dopamine D4 and D2 receptor genes with personality in healthy individuals. <i>Psychiatric Genetics</i> , 2000 , 10, 131-7	2.9	47
182	Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance. <i>International Clinical Psychopharmacology</i> , 2000 , 15, 207-14	2.2	13
181	Reboxetine in the treatment of bulimia nervosa: a report of seven cases. <i>International Clinical Psychopharmacology</i> , 2000 , 15, 351-6	2.2	22
180	Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment. <i>Journal of Affective Disorders</i> , 2000 , 60, 61-74	6.6	97
179	The importance of treatment acceptability to patients. <i>International Journal of Psychiatry in Clinical Practice</i> , 2000 , 4, 25-34	2.4	11
178	Prevalence and distribution of hepatitis C subtypes in patients with opioid dependence. <i>European Addiction Research</i> , 2000 , 6, 198-204	4.6	18
177	Genome scan for susceptibility loci for schizophrenia. <i>Neuropsychobiology</i> , 2000 , 42, 175-82	4	63
176	Seasonal variation of availability of serotonin transporter binding sites in healthy female subjects as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. <i>Biological Psychiatry</i> , 2000 , 47, 158-60	7.9	61
175	[123I]-beta-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. <i>Biological Psychiatry</i> , 2000 , 47, 482-9	7.9	176
174	Association study of schizophrenia spectrum disorders and dopamine D3 receptor gene: is schizoaffective disorder special?. <i>Psychiatry Research</i> , 2000 , 96, 179-83	9.9	12
173	Reboxetine: the first selective noradrenaline re-uptake inhibitor. <i>Expert Opinion on Pharmacotherapy</i> , 2000 , 1, 771-82	4	112
172	Review of quetiapine and its clinical applications in schizophrenia. <i>Expert Opinion on Pharmacotherapy</i> , 2000 , 1, 783-801	4	73
171	Recurrent brief depression: A frequent syndrome in clinical practice. <i>International Journal of Psychiatry in Clinical Practice</i> , 2000 , 4, 195-9	2.4	4
170	A time of opportunity in schizophrenia. <i>International Journal of Psychiatry in Clinical Practice</i> , 2000 , 4, 63-5	2.4	5
169	Suicide by antidepressant intoxication identified at autopsy in Vienna from 1991-1997: the favourable consequences of the increasing use of SSRIs. <i>European Neuropsychopharmacology</i> , 2000 , 10, 133-42	1.2	36
168	Treatment of patients with delirium. <i>American Journal of Psychiatry</i> , 2000 , 157, 1711	11.9	5
167	Social functioning in depression: a review. <i>Journal of Clinical Psychiatry</i> , 2000 , 61, 268-75	4.6	363
166	Is paranoid schizophrenia the most common subtype? Comparison of subtype diagnoses by Japanese and European psychiatrists, using the summaries of the same patients. <i>Psychopathology</i> , 1999 , 32, 98-106	3.4	5

165	Buprenorphine versus methadone maintenance for the treatment of opioid dependence. <i>Addiction</i> , 1999 , 94, 1337-47	4.6	116
164	Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1999 , 249 Suppl 2, I11-I114	5.1	18
163	In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. <i>Psychopharmacology</i> , 1999 , 141, 175-81	4.7	63
162	Osteopenia in anorexia nervosa: specific mechanisms of bone loss. <i>Journal of Psychiatric Research</i> , 1999 , 33, 349-56	5.2	50
161	Mirtazapine in seasonal affective disorder (SAD): a preliminary report. <i>Human Psychopharmacology</i> , 1999 , 14, 59-62	2.3	19
160	Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1999 , 249 Suppl 4, 83-9	5.1	35
159	Atypical eating disorder in a male patient. <i>International Journal of Psychiatry in Clinical Practice</i> , 1999 , 3, 137-9	2.4	2
158	The citalopram challenge test in patients with major depression and in healthy controls. <i>Psychiatry Research</i> , 1999 , 88, 75-88	9.9	65
157	Treatment of severe mania with intravenous magnesium sulphate as a supplementary therapy. <i>Psychiatry Research</i> , 1999 , 89, 239-46	9.9	31
156	In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment. <i>European Neuropsychopharmacology</i> , 1999 , 9, 177-9	1.2	37
155	Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients. <i>European Neuropsychopharmacology</i> , 1999 , 10, 17-20	1.2	100
154	Possible association between childhood absence epilepsy and the gene encoding GABRB3. <i>Biological Psychiatry</i> , 1999 , 46, 997-1002	7.9	53
153	Anticipation in schizophrenia. <i>Schizophrenia Research</i> , 1999 , 35, 25-32	3.6	24
152	Tryptophan depletion. <i>International Clinical Psychopharmacology</i> , 1999 , 14, 313-316	2.2	14
151	Monoamine depletion in non-pharmacological treatments for depression. <i>Advances in Experimental Medicine and Biology</i> , 1999 , 467, 29-33	3.6	7
150	Light Treatment in Depression(SAD, s-SAD & non-SAD) 1999 , 409-416		3
149	Pharmacokinetic-pharmacodynamic modeling of tolerance to the prolactin-secreting effect of chlorprothixene after different modes of drug administration. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1999 , 291, 547-54	4.7	17
148	First-episode schizophrenia: the importance of early intervention and subjective tolerability. <i>Journal of Clinical Psychiatry</i> , 1999 , 60 Suppl 23, 5-9	4.6	9

147	Myo-inositol in depressive and healthy subjects determined by frontal 1H-magnetic resonance spectroscopy at 1.5 tesla. <i>Journal of Psychiatric Research</i> , 1998 , 32, 411-20	5.2	83
146	Social phobia: the nature of the disorder. <i>Journal of Affective Disorders</i> , 1998 , 50 Suppl 1, S3-9	6.6	20
145	Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123I-IBZM SPECT study. <i>Psychopharmacology</i> , 1998 , 136, 367-73	4.7	43
144	Cerebral CT findings in male opioid-dependent patients: stereological, planimetric and linear measurements. <i>Psychiatry Research - Neuroimaging</i> , 1998 , 83, 139-47	2.9	54
143	Low frontal electroencephalographic coherence in neuroleptic-free schizophrenic patients. <i>Biological Psychiatry</i> , 1998 , 44, 438-47	7.9	66
142	What young men do. <i>International Journal of Psychiatry in Clinical Practice</i> , 1998 , 2, 156	2.4	
141	Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. <i>Schizophrenia Research</i> , 1998 , 32, 101-6	3.6	102
140	IBZM-SPECT imaging of dopamine D(2) receptors with typical and atypical antipsychotics. <i>European Psychiatry</i> , 1998 , 13, 9s-14s	6	5
139	IBZM-SPECT imaging of dopamine D2 receptors with typical and atypical antipsychotics. <i>European Psychiatry</i> , 1998 , 13, 9s-14s	6	
138	Transcultural study of schizophrenic delusions. Tokyo versus Vienna and Tübingen (Germany). <i>Psychopathology</i> , 1998 , 31, 59-68	3.4	51
137	D2-dopamine receptor occupancy measured by IBZM-SPECT in relation to extrapyramidal side effects. <i>Pharmacopsychiatry</i> , 1998 , 31, 159-62	2	22
136	Focus on social functioning in depression. <i>International Journal of Psychiatry in Clinical Practice</i> , 1998 , 2, 241-3	2.4	2
135	Enlarged cerebrospinal fluid spaces in opiate-dependent male patients: a stereological CT study. <i>Neuropsychobiology</i> , 1998 , 38, 80-3	4	18
134	Pathological regional cerebral blood flow in opiate-dependent patients during withdrawal: a HMPAO-SPECT study. <i>Neuropsychobiology</i> , 1998 , 37, 194-9	4	47
133	How much do novel antipsychotics benefit the patients?. <i>International Clinical Psychopharmacology</i> , 1998 , 13 Suppl 3, S71-7	2.2	8
132	Risperidone and olanzapine. <i>International Clinical Psychopharmacology</i> , 1998 , 13, 253-262	2.2	36
131	Mirtazapine in recurrent brief depression. <i>International Clinical Psychopharmacology</i> , 1998 , 13, 39-40	2.2	15
130	Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression. <i>International Clinical Psychopharmacology</i> , 1998 , 13, 83-6	2.2	11

129	Occurrence of trazodone-induced delirium. <i>International Clinical Psychopharmacology</i> , 1998 , 13, 225-8	2.2	7
128	Effects of tryptophan depletion in drug-free depressed patients who responded to total sleep deprivation. <i>Archives of General Psychiatry</i> , 1998 , 55, 167-72		53
127	Effects of tryptophan depletion in fully remitted patients with seasonal affective disorder during summer. <i>Psychological Medicine</i> , 1998 , 28, 257-64	6.9	48
126	Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder. <i>Psychological Medicine</i> , 1998 , 28, 923-33	6.9	65
125	Effects of tryptophan depletion vs catecholamine depletion in patients with seasonal affective disorder in remission with light therapy. <i>Archives of General Psychiatry</i> , 1998 , 55, 524-30		125
124	Paroxetine in a patient with obsessive-compulsive disorder, anorexia nervosa and schizotypal personality disorder. <i>Journal of Psychiatry and Neuroscience</i> , 1998 , 23, 179-80	4.5	6
123	Comments on "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" by Tran and Associates. <i>Journal of Clinical Psychopharmacology</i> , 1998 , 18, 353-6	1.7	16
122	(Potentielle) Antipsychotika mit neuartigen Wirkmechanismen 1998 , 489-499		
121	Depression: a long-term illness and its treatment. <i>International Clinical Psychopharmacology</i> , 1998 , 13 Suppl 6, S23-6	2.2	5
120	Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia. <i>International Clinical Psychopharmacology</i> , 1998 , 13, 253-62	2.2	6
119	IBZM-SPECT imaging of dopamine D(2) receptors with typical and atypical antipsychotics. <i>European Psychiatry</i> , 1998 , 13 Suppl 1, 9s-14s	6	1
118	Treatment of seasonal affective disorder (SAD) with hypericum extract. <i>Pharmacopsychiatry</i> , 1997 , 30 Suppl 2, 89-93	2	24
117	EPOS: Increasing our understanding of the treatment of schizophrenia; Start of a prospective referenced cohort study of sertindole in clinical practice. <i>International Journal of Psychiatry in Clinical Practice</i> , 1997 , 1, 197-202	2.4	3
116	New aspects of diagnosis and pharmacotherapy of eating disorders. <i>International Journal of Psychiatry in Clinical Practice</i> , 1997 , 1, 21-35	2.4	9
115	Treatment of obsessive compulsive disorder: Algorithms for pharmacotherapy. <i>International Journal of Psychiatry in Clinical Practice</i> , 1997 , 1 Suppl 1, S17-23	2.4	2
114	Rapid tryptophan depletion in drug-free depressed patients with seasonal affective disorder. <i>American Journal of Psychiatry</i> , 1997 , 154, 1153-5	11.9	41
113	Effects of tryptophan depletion on drug-free patients with seasonal affective disorder during a stable response to bright light therapy. <i>Archives of General Psychiatry</i> , 1997 , 54, 133-8		110
112	Treatment of unipolar major depression: Algorithms for pharmacotherapy. <i>International Journal of Psychiatry in Clinical Practice</i> , 1997 , 1 Suppl 1, S5-7	2.4	5

111	A risk-benefit assessment of mirtazapine in the treatment of depression. <i>Drug Safety</i> , 1997 , 17, 251-64	5.1	49
110	Pramipexole as adjunct to haloperidol in schizophrenia. Safety and efficacy. <i>European Neuropsychopharmacology</i> , 1997 , 7, 65-70	1.2	29
109	Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline. <i>European Neuropsychopharmacology</i> , 1997 , 7, 115-24	1.2	25
108	S.07.02 Therapeutic sleep deprivation: Lessons for psychopharmacology?. <i>European Neuropsychopharmacology</i> , 1997 , 7, S91-S92	1.2	
107	P.2.069 123I IBZM spect imaging of dopamine-2 receptors in psychotic patients treated with zotepine. <i>European Neuropsychopharmacology</i> , 1997 , 7, S215	1.2	2
106	P.6.078 Personality traits in affective disorders as hints to biological disturbances. <i>European Neuropsychopharmacology</i> , 1997 , 7, S288	1.2	2
105	P.6.079 Risperidone in Gilles de la Tourette syndrome patients unresponsive to typical neuroleptics. <i>European Neuropsychopharmacology</i> , 1997 , 7, S288	1.2	
104	P.6.083 Enhanced striatal dopamine transporter activity in drug naive and previously treated patients with gilles de la tourette syndrome (GTS): A [123I]-ECIT SPECT-study. <i>European Neuropsychopharmacology</i> , 1997 , 7, S289-S290	1.2	
103	Sertindole and dopamine D2 receptor occupancy. <i>Biological Psychiatry</i> , 1997 , 42, 161S	7.9	3
102	Diagnosis and Treatment of Subsyndromal Seasonal Affective Disorder 1997 , 167, 11-20		6
101	Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1997 , 247, 291-6	5.1	22
100	Previous treatment as a confounding variable in studies with novel antipsychotics: two cases of high dopamine-2 receptor occupancy with quetiapine. <i>Psychopharmacology</i> , 1997 , 133, 102-5	4.7	15
99	IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. <i>Psychopharmacology</i> , 1997 , 133, 323-8	4.7	55
98	The Place of Milnacipran in the Treatment of Depression. <i>Human Psychopharmacology</i> , 1997 , 12, S135-S141		6
97	Suicidal tendencies as a complication of light therapy for seasonal affective disorder: a report of three cases. <i>Journal of Clinical Psychiatry</i> , 1997 , 58, 389-92	4.6	40
96	Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine. <i>Journal of Clinical Psychopharmacology</i> , 1997 , 17 Suppl 1, 19S-28S	1.7	30
95	Low plasma thyroid indices of depressed patients are attenuated by antidepressant drugs and influence treatment outcome. <i>Pharmacopsychiatry</i> , 1996 , 29, 180-6	2	39
94	Risperidone in the treatment of Gilles de la Tourette Syndrome. <i>European Neuropsychopharmacology</i> , 1996 , 6, S4-163	1.2	

93	Circadian profiles of cortisol, prolactin, and thyrotropin in seasonal affective disorder. <i>Biological Psychiatry</i> , 1996 , 39, 157-70	7.9	38
92	Bright light therapy stabilizes the antidepressant effect of partial sleep deprivation. <i>Biological Psychiatry</i> , 1996 , 39, 16-21	7.9	128
91	D2 Receptor imaging (SPECT) as a tool for measuring the efficacy and side-effect profile of treatment with neuroleptics. <i>Biological Psychiatry</i> , 1996 , 39, 564	7.9	2
90	Temporal lobe dysfunction and correlation of regional cerebral blood flow abnormalities with psychopathology in schizophrenia and major depression--a study with single photon emission computed tomography. <i>Psychiatry Research - Neuroimaging</i> , 1996 , 68, 1-10	2.9	34
89	Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone. <i>Psychiatry Research - Neuroimaging</i> , 1996 , 68, 23-30	2.9	16
88	Schizophrenia and the dopamine-beta-hydroxylase gene: results of a linkage and association study. <i>Psychiatric Genetics</i> , 1996 , 6, 17-22	2.9	26
87	[123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. <i>American Journal of Psychiatry</i> , 1996 , 153, 183-90	11.9	50
86	Carbohydrate-deficient transferrin as a screening marker for drinking in a general hospital population. <i>Alcohol and Alcoholism</i> , 1996 , 31, 249-56	3.5	41
85	Carbohydrate-deficient transferrin as a marker of alcohol intake: a study with healthy subjects. <i>Alcohol and Alcoholism</i> , 1996 , 31, 265-71	3.5	62
84	Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. <i>International Clinical Psychopharmacology</i> , 1996 , 11 Suppl 4, 35-9	2.2	72
83	Poststroke depression and fluoxetine. <i>American Journal of Psychiatry</i> , 1996 , 153, 446-7	11.9	17
82	Therapeutischer Schlafentzug und antidepressive Medikation 1996 , 55-67		
81	Schlafentzug bei Therapieresistenz auf Antidepressiva 1996 , 107-122		
80	Die Diagnose der rezidivierenden kurzdauernden Depression bei einem ambulanten Patientengut 1996 , 209-211		
79	Nebenwirkungen der Lichttherapie bei der Behandlung psychischer Erkrankungen 1996 , 232-236		
78	Kombination von Schlafentzug und Lichttherapie zur Behandlung depressiver Störungen 1996 , 69-80		
77	Rückfallverhütung nach Schlafentzug 1996 , 466-469		
76	Metabolismustheorie des therapeutischen Schlafentzugs 1996 , 460-465		

75	Risk of suicide in depression and its implication for psychopharmacological treatment. <i>International Clinical Psychopharmacology</i> , 1996 , 11, 71-9	2.2	19
74	Pharmacokinetics of chlorprothixene after single intravenous and oral administration of three galenic preparations. <i>Arzneimittelforschung</i> , 1996 , 46, 247-50		2
73	beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. <i>Journal of Neural Transmission</i> , 1995 , 100, 247-56	4.3	103
72	Diagnosis and clinical course in mood disorders and depression subtypes. <i>Depression</i> , 1995 , 3, 125-128		3
71	A controlled study of the efficacy and safety of mianserin and amitriptyline in depressive inpatients. <i>Pharmacopsychiatry</i> , 1995 , 28, 249-52	2	14
70	Maintenance ECT for treatment of therapy-resistant paranoid schizophrenia and Parkinson disease. <i>Biological Psychiatry</i> , 1995 , 37, 892-4	7.9	13
69	Seasonal affective disorder in a tropical country: a case report. <i>Psychiatry Research</i> , 1995 , 56, 11-5	9.9	8
68	P-4-32 IBZM-SPECT and D2 dopamine receptor occupancy: Different profiles with atypical neuroleptics. <i>European Neuropsychopharmacology</i> , 1995 , 5, 337	1.2	3
67	Recurrent Brief Depression. <i>CNS Drugs</i> , 1995 , 4, 222-229	6.7	5
66	Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. <i>International Clinical Psychopharmacology</i> , 1995 , 10 Suppl 4, 25-35	2.2	60
65	Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. <i>International Clinical Psychopharmacology</i> , 1995 , 9 Suppl 4, 33-40	2.2	106
64	Antidepressant efficacy in relation to item analysis and severity of depression: a placebo-controlled trial of fluvoxamine versus imipramine. <i>International Clinical Psychopharmacology</i> , 1995 , 9 Suppl 4, 3-12	2.2	33
63	Treatment indications for light therapy. <i>Acta Neuropsychiatrica</i> , 1995 , 7, 44-6	3.9	1
62	Trigeminal neuralgic syndrome after bright light therapy. <i>American Journal of Psychiatry</i> , 1995 , 152, 1237-1239	11.9	7
61	Transcranial magnetic stimulation (TMS) in the treatment of major depression: a pilot study. <i>Human Psychopharmacology</i> , 1995 , 10, 305-310	2.3	120
60	Involvement of mesial-temporal structures in rapid cycling mood disorders?. <i>Human Psychopharmacology</i> , 1995 , 10, 475-480	2.3	1
59	Do SSRIs differ in their antidepressant efficacy. <i>Human Psychopharmacology</i> , 1995 , 10 Suppl 3, S163-S172	17.3	16
58	Algorithms for the treatment of subtypes of unipolar major depression. <i>Psychopharmacology Bulletin</i> , 1995 , 31, 475-82	0.9	12

57	Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 1995 , 33, 646-52	2	9
56	Hypericum in the Treatment of Seasonal Affective Disorders. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1994 , 7, 29-33	3.8	32
55	Use of light therapy in German psychiatric hospitals. <i>European Psychiatry</i> , 1994 , 9, 288-292	6	15
54	Hypericum in the treatment of seasonal affective disorders. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1994 , 7 Suppl 1, S29-33	3.8	69
53	Clinical response to sleep deprivation and auditory-evoked potentials--preliminary results. <i>Pharmacopsychiatry</i> , 1994 , 27, 70-1	2	7
52	Efficacy of new generation antidepressants: meta-analysis of imipramine-controlled studies. <i>Pharmacopsychiatry</i> , 1994 , 27, 215-23	2	22
51	Evidence for a seasonal form of recurrent brief depression (RBD-seasonal). <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1994 , 244, 205-10	5.1	6
50	Safety and antidepressant efficacy of selective serotonin re-uptake inhibitors. <i>Human Psychopharmacology</i> , 1994 , 9, 1-12	2.3	34
49	Efficacy, safety, and indications for tricyclic and newer antidepressants. <i>Depression</i> , 1994 , 2, 127-137		16
48	Antidepressant side effects and adverse reactions. <i>Depression</i> , 1994 , 2, 138-144		2
47	Risperidone for Tourette® syndrome. <i>Lancet, The</i> , 1994 , 344, 1577-8	40	36
46	Behandlungsergebnisse mit präsynaptischen und postsynaptischen Dopamin-Agonisten bei Minussymptomatik 1994 , 221-239		1
45	Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. <i>European Neuropsychopharmacology</i> , 1993 , 3, 13-21	1.2	54
44	Is severe depression a different illness? The pharmacological evidence. <i>European Neuropsychopharmacology</i> , 1993 , 3, 215-217	1.2	4
43	Hormonal markers of response to antidepressive treatment. <i>European Neuropsychopharmacology</i> , 1993 , 3, 321-322	1.2	
42	Application of transcranial magnetic stimulation in treatment of drug-resistant major depression—report of two cases. <i>Human Psychopharmacology</i> , 1993 , 8, 361-365	2.3	138
41	Nicht-trizyklische Antidepressiva 1993 , 105-268		2
40	Objektivierung der quantitativen Lichtexposition während Lichttherapie durch kontinuierliche photometrische Aufzeichnung 1993 , 268-271		

39	Hormonelle Verlaufparameter unter Elektrokrampftherapie bei Patientinnen mit therapieresistenter Depression 1993 , 186-190		1
38	Sicherheit und antidepressive Wirksamkeit von spezifischen Serotonin-Wiederaufnahmehemmern (SSRIs) 1993 , 163-182		1
37	Quantitatives EEG und Ansprechen auf therapeutischen Schlafentzug bei depressiven Patienten 1993 , 217-220		1
36	Tissue-specific regulation of vasoactive intestinal peptide messenger ribonucleic acid levels by estrogen in the rat. <i>Endocrinology</i> , 1992 , 130, 1796-801	4.8	18
35	Comparative efficacy of antidepressants. <i>Drugs</i> , 1992 , 43 Suppl 2, 11-22; discussion 22-3	12.1	97
34	Early clinical results with the neuroleptic roxindole (EMD 49,980) in the treatment of schizophrenia--an open study. <i>European Neuropsychopharmacology</i> , 1992 , 2, 91-5	1.2	10
33	Thyroid hormones, body temperature, and antidepressant treatment. <i>Biological Psychiatry</i> , 1992 , 31, 859-62	7.9	23
32	Recurrent brief depression and its relationship to seasonal affective disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1992 , 242, 20-6	5.1	25
31	Therapeutischer Schlafentzug und Resistenz auf Antidepressiva [Neuroendokrinologische und klinische Befunde 1992 , 446-448		
30	Reduzierte Amplitude zirkadianer Hormonprofile bei Patienten mit saisonal abhängiger Depression (SAD) 1992 , 356-359		
29	Mapping von EEG und EP unter therapeutischem Schlafentzug bei Patienten mit Major Depression [Erste Ergebnisse 1992 , 285-288		
28	Evaluation of seasonality in six clinical populations and two normal populations. <i>Journal of Psychiatric Research</i> , 1991 , 25, 75-87	5.2	128
27	Abnormal pituitary-adrenal responses to corticotropin-releasing hormone in patients with seasonal affective disorder: clinical and pathophysiological implications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991 , 72, 1382-7	5.6	121
26	Contrasts between symptoms of summer depression and winter depression. <i>Journal of Affective Disorders</i> , 1991 , 23, 173-83	6.6	49
25	Therapeutic sleep deprivation and antidepressant medication in patients with major depression. <i>European Neuropsychopharmacology</i> , 1991 , 1, 107-11	1.2	14
24	Immunological correlates of seasonal fluctuations in mood and behavior and their relationship to phototherapy. <i>Psychiatry Research</i> , 1991 , 36, 253-64	9.9	12
23	Jahreszeit und Befindlichkeit in der Allgemeinbevölkerung. <i>Monographien Aus Dem Gesamtgebiete Der Psychiatrie</i> , 1991 ,		8
22	Multiple hormone responses to stimulation with dl-fenfluramine in patients with major depression before and after antidepressive treatment. <i>Pharmacopsychiatry</i> , 1990 , 23, 76-84	2	28

21	Response to total sleep deprivation before and during treatment with fluvoxamine or maprotiline in patients with major depression--results of a double-blind study. <i>Pharmacopsychiatry</i> , 1990 , 23, 135-42 ²		36
20	Effects of light treatment on core body temperature in seasonal affective disorder. <i>Biological Psychiatry</i> , 1990 , 27, 39-50	7.9	63
19	The effects of phototherapy in the general population. <i>Journal of Affective Disorders</i> , 1990 , 18, 211-9	6.6	51
18	Seasonality in major depressed inpatients. <i>Journal of Affective Disorders</i> , 1990 , 19, 243-8	6.6	33
17	Schlafentzugstherapie Eine Chance bei Antidepressiva-Nonresponse? 1990 , 149-166		11
16	Phototherapy in individuals with and without subsyndromal seasonal affective disorder. <i>Archives of General Psychiatry</i> , 1989 , 46, 837-44		202
15	Epidemiological findings of seasonal changes in mood and behavior. A telephone survey of Montgomery County, Maryland. <i>Archives of General Psychiatry</i> , 1989 , 46, 823-33		492
14	Seasonal changes in mood and behavior: a cluster analytic approach. <i>Psychiatry Research</i> , 1989 , 28, 227-39	3.9	33
13	Judgement of the hypothalamic-pituitary-adrenocortical function in psychiatric patients by betamethasone-induced cortisol suppressibility. <i>Journal of Neural Transmission</i> , 1988 , 74, 161-74	4.3	1
12	Auditory evoked potentials and total sleep deprivation in depressed patients. <i>Psychiatry Research</i> , 1988 , 25, 91-100	9.9	20
11	Nocturnal TSH and prolactin secretion during sleep deprivation and prediction of antidepressant response in patients with major depression. <i>Biological Psychiatry</i> , 1988 , 24, 631-41	7.9	65
10	Phototherapy in subsyndromal seasonal affective disorder (S-SAD) and "diagnosed" controls. <i>Pharmacopsychiatry</i> , 1988 , 21, 428-9	2	25
9	Neurobiology of seasonal affective disorder and phototherapy. <i>Journal of Biological Rhythms</i> , 1988 , 3, 135-54	3.2	72
8	Serotonergically induced hormonal responses and the antidepressant effect of total sleep deprivation in patients with major depression. <i>Psychopharmacology Bulletin</i> , 1988 , 24, 450-3	0.9	12
7	Personality as a dimension of summer and winter depression. <i>Psychopharmacology Bulletin</i> , 1988 , 24, 476-83	0.9	10
6	Dexamethasone suppression test in a pluridiagnostic approach: its relationship to psychopathological and clinical variables. <i>Acta Psychiatrica Scandinavica</i> , 1983 , 68, 31-7	6.5	51
5	Low platelet MAO activity and schizophrenia: sex differences. <i>Acta Psychiatrica Scandinavica</i> , 1981 , 64, 167-74	6.5	18
4	Trazodone and amitriptyline in treatment of depressed inpatients. A double-blind study. <i>Pharmacopsychiatry</i> , 1981 , 14, 167-71	2	22

3	The anticholinergic biperiden in depressive disorders. <i>Pharmacopsychiatry</i> , 1981 , 14, 195-8	2	59
2	Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder		4
1			5